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Epstein-Barr virus (EBV) has infected 95% of the adult population.  Yet, EBV stays as a 
harmless passenger in infected B-cells of nearly every host.  EBV depends on a careful balance 
between the immune system and the virus that becomes evident when the host is 
immunocompromised.  In such individuals, EBV can manifest as one of many associated 
malignancies.  In children who have undergone solid organ transplantation, EBV-driven post-
transplant lymphoproliferative disease (PTLD) can cause significant morbidity and mortality.  
We examined EBV-infected cells in non-diseased pediatric transplant recipients with elevated 
viral loads in their peripheral blood.  Examination of high EBV genome copy cells in high load 
patients with a combined fluorescent in situ hybridization and immunofluorescence procedure 
demonstrated that the majority of high copy cells had no discernible expression of 
immunoglobulin on the surface (Ig-null cells).  Such cells are lacking the crucial survival signal 
provided by an intact BCR and should not survive in the circulation.  By flow cytometry, high 
load patients were shown to have the highest percentage of Ig-null cells in their peripheral blood; 
those with low viral loads and non-detectable viral loads had lower percentages.  The phenotype 
of Ig-null cells was shown to differ from the resting memory B2 phenotype of normal latently 
infected B cells, with variable expression of CD20, CD40, and HLA Class I and II.  Sorting Ig-
null cells from the peripheral blood of high load carriers further demonstrated that in all patients 
 iii
examined, a large portion of the viral load was carried in the Ig-null compartment.  Virus was 
also detected in the Ig-null, CD20- and HLA Class I- compartment, with a variable enrichment 
of the viral load in these compartments from patient to patient.  Ig-null cells have been reported 
in the tumors of other EBV-associated malignancies, including PTLD, but never in the peripheral 
blood or in a non-disease state.  This study has public health relevance because PTLD carries 
significant morbidity and mortality to transplant recipients; the presence in the blood of aberrant 
Ig-null cells which should have followed a program of apoptosis might be a risk factor for the 
development of PTLD or another EBV-associated disease.   
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1. INTRODUCTION 
 
1.1. BIOLOGY OF EPSTEIN-BARR VIRUS 
 
Epstein-Barr virus (EBV) is the prototype of the gamma subfamily of herpesviruses.  This group 
contains the potentially oncogenic herpesviruses, and is composed of the genera 
lymphocryptovirus (LCV) and rhadinovirus (RDV) (123); EBV is also known as human 
herpesvirus 4 (HHV4).  Members of the LCV genus are restricted to primates and are likely to 
have evolved from early primate RDV.  EBV is the only LCV found in humans, while LCVs are 
endemic in both New and Old World primates (14, 37, 46, 61, 82, 85, 120).  
 EBV related disease was first observed in the 1940s, but the causative agent was not 
officially discovered until 1964 (34).  In the initial studies, Denis Burkitt observed characteristic 
extranodal lymphomas in children in regions of Central Africa with holoendemic malaria.  
Because of the epidemiological and clinical characteristics of the lymphomas, an infectious 
etiology was suspected (19).  Subsequently, in a collaboration with Tony Epstein, and his 
graduate student Yvonne Barr the direct observation of EB viral particles was made in cells 
cultured from the lymphoma biopsies sent to London, England by Burkitt(34).  EBV was 
identified as the first human oncogenic virus.  Indeed, a distinguishing characteristic of the 
gamma herpesvirus subfamily is their potential for human malignancy, in combination with 
limited in vitro host range, and establishment of latent infections in lymphocytes (123).  Further, 
LCVs and RSVs have proven to have a close nucleotide and protein sequence relationship, 
which has strengthened the initial classification (10, 30).   
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  In the virion, EBV has a linear double-stranded DNA of 184 kbp (kilobase pairs) (10, 28, 
48, 50).  The genome circularizes into an episome upon infection, locking into a circle a variable 
number of terminal repeats.  This variation depends on the number of tandom repeats in the 
parental genome and can be used, along with other repeated regions in the DNA, to track 
epidemics and group the virus into strains (119).  Based upon its serological responses and 
genomic sequence, EBV has been classified into two types, Type 1 and Type 2 (6, 29, 36, 138).  
While Type 1 is far more common in the western world, Type 2 is prevalent in New Guinea and 
equatorial Africa (57, 75, 99, 168).  HIV-infected individuals and other immunocompromised 
persons often are infected with Type 2, in addition to Type 1 (135, 164, 165).  The only major 
difference between Type 1 and Type 2 is in the genomic sequence encoding for EBV nuclear 
antigens (EBNA) LP, 2, 3A, 3B, and 3C (129).  A schematic of the viral genome, both in its 
linear and circular form is shown in Figure 1 (163).   
 In vitro, EBV has a host cell restriction to B lymphocytes, presumably because the 
required viral receptor, CD 21, is only expressed on such cells (40).  CD21 is a member of the 
C3d component of the complement system (81, 162), and also binds to the EBV glycoprotein 
(gp) 350/220 outer envelope protein (109, 149, 150).  After binding, CD21 aggregates, and EBV 
is internalized into cytoplasmic vesicles.  Gp85 is required for envelope fusion to B lymphocytes 
(23, 108).  One of EBV’s defining characteristics is its ability to transform B cells into latently 
infected B-lymphoblastoid cell lines (LCLs), in vitro (62, 123, 145).  In some circumstances, 
EBV can also infect epithelial cells.  In vitro infection can be established in epithelial cells, albeit 
at a very low level and inefficiently (112, 136, 137).  However, in vivo, epithelial cells are fully 
permissive for a lytic EB viral infection (112, 137). 
2 
  
 
 
Figure 1. The circularized EBV genome (163).  
 
 
Figure 2. The linearized EBV genome (163).  
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 1.2. EPSTEIN-BARR VIRAL LATENCY AND ASSOCIATED PROTEINS 
 
Nearly all types of human primary B cells, with the exception of plasma cells, can be infected 
with EBV.  The outcome of EBV infection in this scenario is a continuously proliferating 
lymphoblastoid cell line, with minimal or nondetectable virus replication and a characteristic 
pattern of viral gene expression, termed Latency III (66, 118).  Latency III includes the 
expression of two Epstein-Barr Encoded RNAs (EBERS), BAMHI A RNAs, six viral nuclear 
antigen transcripts (EBNA 1, 2, 3A, 3B, 3C, and LP), and 3 latent membrane protein (LMP) 
transcripts, LMP1, LMP2A, and LMP2B (123).  A brief description of form and function for 
each of these products is detailed below. 
 EBERS are small, nonpolyadenylated RNAs encoded by the virus.  EBER transcripts are 
made by RNA polymerase III and constitute the most common viral transcript in an infected cell 
(7, 70).  Thousands of EBERS localize to the cell nucleus, where they interact with specific 
cellular proteins (69).  While function(s) for the EBERS have been proposed, none have been 
confirmed.  It has been hypothesized that the EBERs have an anti-interferon effect (147) and/or 
are involved in RNA splicing (52), but neither hypothesis has been confirmed.  Further testing 
must be conducted to deduce their precise role. 
 EBNA1 is a sequence specific DNA binding protein that binds to the origin of plasmid 
replication (oriP) and is the virus genome maintenance protein in EBV immortalized 
lymphocytes (84).  It is a very stable protein and is composed of 641 amino acids with a size of 
76 kilodaltons (kd) (123).  EBNA1 is thought to be expressed in all EBV infected cells, although 
it is not always detectable.  OriP is composed of two elements, the family of repeats (FR) and the 
dyad symmetry element (DS) (60, 121, 122).  FR facilitates transcription and replication of the 
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 EBV epsiome, and further terminates the reaction.  DS is the origin from which replication 
moves in a bi-directional manner from the DS (43).  Each molecule of EBV DNA can only 
replicate once per each cellular S phase (1, 166) and the newly replicated episomes are 
distributed randomly to the newly formed cells (144).  
 EBNA2 is an upregulator of virus and cellular gene expression, and the expression of the 
other viral proteins found in immortalized cells is dependent on this function.  Its RNA is 
transcribed upon initiation of an EBV infection in a primary B lymphocyte.  Thus, without 
EBNA2, transformation of B cells into LCLs does not occur (123).  Cellular genes that are 
upregulated as a result of expression of EBNA2 include CD23 (159), CD21 (3, 25, 161), and c-
myc (72).  Between EBV Types 1 and 2, EBNA2 differs the most of any other latency associated 
protein, resulting in a much more rapidly growing LCL for EBV Type 2 than Type 1 (123).   
 EBNA3A, B, and C are tandemly located on the EBV genome, and their mRNAs are 
expressed at very low levels in the latently infected cell (123).  These three proteins range in size 
from 925-1069 amino acids and are very stable proteins (132).  There is a weak homology in the 
N terminus of these three proteins.  EBNA 3A and C have shown to be essential for the growth 
transformation of B lymphocytes (155) and their subsequent survival, but an essential function 
for EBNA3B has not be deduced yet.  Because of the highly immunogenic nature of EBNA 3B, 
it is believed to be important for recognition by the immune system.  As a group, the EBNA3 
proteins function as transcriptional transactivators and contribute to upregulation of cellular gene 
expression.  Further, peptides derived from the EBNA 3’s are the primary targets for the 
recognition of immortalized cells by cytotoxic T lymphocytes.  
 EBNA-LP, like EBNA2, is transcribed at the beginning of EBV infection and at very 
high levels.  Because the N terminus of EBNA-LP is derived from the W1 and W2 repeat regions 
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 (repeating 22/44 aa segments) of the EBV genome, this protein differs in size in cells infected 
with different EBV isolates (117).  The carboxy terminus is 45 amino acids long.  This protein is 
thought to cooperate with EBNA2 in the upregulation of cellular and viral gene products 
essential for the establishment of LCLs and viral latency (58, 113).  Further, EBNA-LP has been 
suggested to interact with RNA transcripts and be important for RNA processing (83).   
 LMP1 is the latent protein responsible for many of the changes associated with EBV 
infection of a primary B lymphocyte.  These include cell clumping, increased expression of 
various cell surface markers and cell adhesion molecules, increased vimentin production (with 
which LMP1 associates), protection from apoptosis, and increased villous projections (55, 63, 
128, 160).  As such, LMP1 is necessary for the growth transformation of B lymphocytes (73).  
LMP1 is 63 Kd with 6 transmembrane domains, a short N-terminal cytoplasmic end, and a long 
C-terminal cytoplasmic tail.  LMP1 is homologous to the tumor necrosis factor receptor CD40, 
both structurally and functionally (105).  LMP1 is very unstable, with a half-life of only 1.5-7 
hours, depending on the cell type.  LMP1 is believed to be ubiquinated and rapidly degraded by 
the proteosome pathway in order to avoid toxic levels of the protein in the cell (88, 89, 130).  
However, LMP1 transcripts are much more abundant than the EBNA transcripts in latency (39, 
131).   
 LMP2 is an integral membrane protein with two isoforms (42, 90).  LMP2A and LMP2B 
differ in their first exon; 2A has a 119 aa amino-terminal cytoplasmic domain, while 2B lacks 
this domain (130).  The 2nd exon forward encodes for a transmembrane region consisting of 12 
integral membrane sequences, followed by a short carboxy-terminal tail (130).  Because the 
LMP2 transcript is encoded across the fused terminal repeat region, LM2 is only expressed in 
cells after circularization of the EBV genome.  LMP2A associates with src family tyrosine 
6 
 kinases of B lymphocytes (91), but neither 2A nor 2B is essential for the transformation of B 
cells into LCLs or their subsequent survival (77, 92, 93, 94, 124, 140).  Rather, LMP2A is 
thought to block the activating signals that would occur when CD19 or sIg are cross-linked on 
the cell surface (100, 101).  Such activation would induce the initiation of lytic replication.  
Further, LMP2A is thought to provide survival and anti-differentiation signals to some B cells, 
especially those lacking immunoglobulin on their cell surface (21).  A definitive role for LMP2B 
has not been established.   
 
1.3. EPSTEIN-BARR VIRAL PRIMARY AND PERSISTENT INFECTION 
 
 Latent infections by EBV have been categorized according to the patterns of viral gene 
expression detected and are related to the cell types involved and whether they are studied in 
vitro or in vivo.  Latency 0 is observed in peripheral blood lymphocytes (PBLs) of healthy 
carriers and is defined as having no viral products expressed, with the possible exception of 
LMP2A.  Latency 1, found in Burkitt’s lymphoma cells, has the expression of only EBNA1, 
while Latency 2, seen in Hodgkin’s and other virus-associated malignancies is defined as having 
the expression of both LMP1 and LMP2, in addition to EBNA1 (123).  Latency III is 
characteristic of cells immortalized in vitro but is also detected in vivo in reactive lymph nodes 
of patients with active EBV infections.  These latencies will be discussed in more detail in future 
sections.  For now, a summary of their distribution is shown in Table 1.   
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 Table 1. Programs of EBV Latency 
 
 
 
Latency 
Program 0 I II III 
 
LMP1 No No Yes Yes 
LMP2 Yes Yes Yes Yes 
EBNA1 No Yes Yes Yes 
EBNA2 No No No Yes 
EBNA3’s No No No Yes 
EBNA-LP No No No Yes 
EBERS Yes Yes Yes Yes 
Expression 
site 
Resting, 
memory B 
cell 
Burkitt’s 
Lymphoma 
Hodgkin’s 
Lymphoma PTLD, IM 
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 Prevalence of EBV infection is near 100% in the developing world, and 95% in the industrialized 
nations (123).  It is transmitted primarily via saliva, but can also be passed through the blood, or 
along with the donor organ in solid organ transplantation.  Normal parent to child contact in the 
first years of life is responsible for most primary infections in children (54).  Such infections in 
early childhood are nearly always asymptomatic; but primary infections in adolescence or early 
adulthood can be symptomatic and manifested as infectious mononucleosis (IM) (35).  Why 
some cases of EBV infection post childhood are symptomatic, while others are not is still 
unknown.   
 IM has been described as a self-limiting lymphoproliferative disease in which up to 25% 
of peripheral blood memory B cells are infected with the virus (151).  It is characterized by the 
presence of atypical mononuclear cells stemming from mostly CD8+ T lymphocytes, as well as 
CD4+ T lymphocytes and activated natural killer cells (NK) (123).  Extensive proliferation of 
infected B cells and cytotoxic T cells destroy the normal histological compartments of tonsillar 
tissue, and a massive immune response is generated that clears the blood of most infected B cells 
in a few weeks.  Primary CD8+ T cell epitopes are antigenically specific for mainly the EBNA 3 
proteins as well as several immediate early (BZLF1 & BRLF1) and early proteins (BMLF1, 
BMRF1, and BALF2) (140).  By molecular analysis of immunoglobulin variable region genes, it 
has been suggested that EBV-infected B cells do not need to pass through a germinal center 
reaction in order to establish a persistent latent infection (80).  Typical symptoms of IM include 
fever, lymphadenopathy, pharyngitis, and general malaise (123).  Such symptoms can last for 
several weeks, and are primarily due to the overwhelming proinflammatory reaction of the 
immune system (4, 111). 
9 
  Following resolution of primary infection with EBV, a persistent carrier state is 
established.  In a healthy individual this state is characterized by low numbers of latently infected 
B cells in the range of 1 to 50 per one million B cells (74, 104), secretion of low levels of 
infectious virus at mucosal sites with a B cell infiltrate (33, 138), and an antiviral serological 
response characterized by IgG antibodies to EBNA1 and VCA (viral capsid antigen), and often a 
low level anti-gp350 neutralizing antibody (64).  Latently infected cells in the peripheral blood 
of healthy carriers have consistently been characterized as resting memory B2 cells (9, 78, 103, 
104).  These infected cells have a Latency 0 phenotype, with only the LMP2A transcript 
expressed.  The majority of the T cells involved in the massive response specific for EBV 
epitopes, especially to the immediate early and early proteins, die or revert to a resting phenotype 
(22).  However, T cells specific for epitopes, in the EBNA3’s and LMP2 seem to persist and be 
maintained in a stable manner for long duration immunosurveillance (76, 107).  Some CTL 
memory is maintained for the lytic epitopes, at a relatively high level (5, 22, 141, 147), as a 
result of continuous viral shedding at mucosal sites.  The persistent and diverse immune response 
to EBV is probably a result of the latent and persistent nature of the virus, with episodic virus 
reactivations, active replication and virus shedding observed at mucosal sites in the healthy 
infected carrier.   
 Thus, EBV is extremely efficient in its persistence and achieving the balance between 
survival and survival of the host.  By downregulating the Latency II growth transformation 
profile, with its strong immunodominant epitopes, to a Latency 0 profile, the virus in the 
circulating pool of B cells becomes undetectable by immune system.  When the proliferation 
program is expressed, the immunogenicity of a number of essential viral proteins ensures that 
run-away lymphoproliferations are not a mortal threat to the host.  In a healthy 
10 
 immunocompetent individual, EBV is in essence a silent passenger that is easily kept in check by 
immunosurveillance. 
 
1.4. ASSOCIATED MALIGNANCIES OF EPSTEIN-BARR VIRUS 
 
In immunocompromised individuals, the balance between virus reactivation and host 
surveillance is often disrupted.  Reduced CTL precursor frequencies are observed, in conjunction 
with increased viral shedding in the oropharynx and an increase in the viral load in the peripheral 
blood (26, 166).  Studies on immunocompromised individuals have usually focused on HIV+ 
individuals, both children and adult, and organ transplant recipients, both solid organ and bone 
marrow.  In adults, immunosuppression is usually imposed on an already EBV infected 
individual, while children who receive organ transplants or become infected with HIV are often 
EBV negative and must experience a primary infection in the context of immunosuppression.  
Congenitally immunodeficient individuals can also be at risk for diseases associated with EBV.   
 Diseases associated with a congenital immunodeficiency include X-Linked 
lymphoproliferative syndrome (XLP), fatal infectious mononucleosis, and virus-associated 
hemaphagocytic syndrome (VAHS).  A common theme of such diseases is an inability to control 
the massive T-cell proliferation associated with a primary EBV infection, thereby leading to 
hemophagocytosis and many times, death (123).  In rare instances, EBV is linked to 
malignancies even in the immunocompetent host.  
 
1.4.1. Burkitt’s Lymphoma 
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 Burkitt’s Lymphoma (BL), is named for Denis Burkitt who first observed these lymphomas in 
equatorial Africa (19).  The tumors were observed in childhood/early adolescent patients, at a 
yearly incidence of 5-10 cases/100,000 children (18, 96).  Lymphomas present at extranodal 
sites, commonly along the jawline, orbit, central nervous system (CNS), or as an abdominal 
mass.  Morphologically, malignant cells are similar to germinal center B cells, but with 
macrophages interspersed in the tumor, giving it a “starry sky” appearance (123).  The tumors 
are monoclonal, with usually one of three reciprocal translocations.  Besides this endemic form, 
BL has a sporadic and an AIDS-associated form.  Sporadic BL has the same characteristics as 
the endemic form, but occur spontaneously in Europe and the United States, albeit at a much 
lower rate than the endemic form and with less than 100% association with Epstein-Barr virus.  
Similarly, AIDS-associated BL shares a similar morphology to the other forms, both 
cytologically and histologically (44).   
 EBV has a varied association with the different forms of BL.  It is highly associated 
(some reports say 100%) with EBV in the endemic form, while only 20-30% are associated in 
both the sporadic and AIDS-associated form (71, 87, 96).  In EBV-positive BL’s, a latency I 
profile is always expressed, with EBNA1 being the only latent protein detected.  BL cells have 
the phenotype BCL6+, CD10+, CD77+, CD38+, and sIg+, with mutated V genes and often 
ongoing somatic hypermutation (SHM) (80).  Thus, the cellular origin of BL cells has been 
pinpointed to germinal center B cells.   
 
1.4.2. Hodgkin’s Disease 
 
Hodgkin’s Disease (HD) is characterized by a distinct, although small in number, population of 
cells termed Hodgkin and Reed-Sternberg Cells (HRS).  While these cells only make up 1-2 % 
12 
 of a Hodgkin lymphoma, they are large, atypical, malignant cells.  The remaining tumor mass is 
usually made up of non-malignant T and B cells, eosinophils, or other cells (59).  There are 4 
histologic subtypes based on the bulk of cells making up the tumor mass.  The first three types, 
nodular sclerosing, mixed cellularity, and lymphocyte depleted, have been classified together as 
“classical” HD, while the fourth, lymphocyte predominant, is rare and termed “non-classical” 
(59).  HD occurs worldwide, and overall, around 40% of the lymphomas are EBV-positive (51).  
However, in some areas of the world, namely Africa, Asia, and Latin America, nearly 100% of 
childhood HD is associated with EBV.  In immunocompromised individuals, nearly 100% of HD 
are EBV associated (8, 45, 153).  
 The infected HRS cells of EBV positive HD have a Latency II profile, with the 
expression of LMP1, LMP2, and EBNA1.  Classical HD is monoclonal, with the cellular 
derivation of HRS cells being B cells, specifically pre-apoptotic germinal center B cells.  Such 
cells show a loss of B-cell phenotype, and often carry either heavily mutated Ig genes or crippled 
B cells with nonsense mutations or deleterious deletions.  Such mutations stem from the somatic 
hypermutation process occurring in germinal centers, but usually do not lead to a viable B cell.  
Without the proper survival signals normally received in a germinal center reaction, B cells are 
eliminated by apoptosis.  In this case, it is suspected that EBV is delivering the survival signals, 
in the form of LMP2A (surface Ig-mediated signal), and LMP1 (activation of the CD40 
pathway) (80).  Exactly how and why EBV contributes to tumor development is unclear.   
 
1.4.3. Nasopharyngeal Carcinoma 
 
Nasopharyngeal carcinoma (NPC) is a tumor of epithelial tissue arising from the fossa of 
Rosenmuller (an anatomical site) (123).  Two classifications exist: keratinizing and non-
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 keratinizing, with the main difference being level of differentiation.  Different incidence rates 
exist for different geological locations.  In the western world, NPC is very rare 
(0.5/100,000/year) and has an equal distribution of keratinizing and non-keratinizing types.  In 
Southeast Asian populations, as well as in the Inuit, NPC is much more common, with an 
incidence of 25/100,000/year, and mainly of the non-keratinizing type.  This suggests that 
genetic factors may work with environmental factors to increase the risk of NPC in certain ethnic 
populations (123).   
 Nearly all cases of both keratinizing and non-keratinizing NPC are EBV positive (110, 
114).  Elevated serum antiviral antibody titers are observed in NPC patients, with a distinctive 
detectable level of IgA antibody responses and elevated IgG levels to VCA and EA (65).  
Monitoring for these antibody levels in an at-risk population has been used as a diagnostic 
screening tool.  Another marker for NPC is EBV DNA in the serum.  At a basic level, NPCs 
have been described as having a Latency II pattern of EBV gene expression, similar to HD 
(LMP1 & 2, EBNA1) (17, 20).  Recently, a more accurate description of Latency I/II has been 
conducted for NPCs and the level of both LMP1 and 2 appears to be very low and at times 
undetectable (42, 86).  NPC tumor cells express HLA Class I and II, CD40, CD54, CD70, CD80, 
CD86, and CD95, and have a cellular phenotype typical of epithelial:lymphoid interactions (2, 
133). 
 
1.4.4. AIDS-associated Lymphomas 
 
As mentioned above, HIV+ persons are at an elevated risk for the development of EBV-
associated malignancies.  Up to 10% of this population will develop a B-cell lymphoma (12).  
The diversity of the B-cell lymphomas is wide, with estimates of EBV positivity hovering 
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 around 50% (44).  The first class of AIDS lymphomas occurs when HIV+ individuals are 
profoundly immunocompromised and experiencing full-fledged AIDS.  The cells of these 
lymphomas contain and express EBV, and resemble post-transplant lymphoproliferative disease 
(see below) in many aspects (95).  The expression of EBV genes is varied, but is usually EBNA2 
and LMP1 and the lymphoma cells appear to arise from mature post-germinal center progenitors 
(31).  Such lymphomas typically present as polymorphic B-cell hyperplasia or monomorphic 
immunoblastic lymphomas (95).  Other categories of AIDS-associated lymphomas include 
Burkitt’s Lymphoma (as described previously), primary effusion lymphomas, and classical 
Hodgkin’s Disease.  In HIV+ children, the second most common tumor is leiomyosarcoma (a 
smooth muscle tumor).  Nearly all such tumors in immunocompromised children are EBV 
associated, although neither the mechanism by which EBV infects smooth muscle, nor the latent 
state of EBV is known (97). 
 
1.4.5. Post-Transplant Lymphomas 
 
Post-transplant lymphoproliferative disease (PTLD) is an important factor in both solid organ 
transplantation (SOT) and hematopoietic stem cell transplant (HSCT).  This potentially fatal 
disease has many diverse presentations, ranging from reactive polyclonal hyperplasias to non-
Hodgkin’s lymphomas (53).  Ninety percent of PTLDs are EBV positive and are closely linked 
to the immunosuppression associated with transplantation (115, 116).  Depletion of cellular 
immunity in such patients decreases the chances of rejection and graft versus host disease, but 
also disrupts the balance between EBV and its control by the EBV-specific cellular immune 
surveillance.  Patients are at the highest risk of PTLD in the first year following transplant (53), 
but may also occur in patients years after the transplant.  Incidence rates of PTLD have a broad 
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 range from 1-2% after HSCT (13, 27), to 1-10% following kidney, lung, heart, and liver 
transplant, and up to 20% following small bowel transplant (16, 32, 41).  Differences in the 
incidence rates are most likely a consequence of many factors, including type, intensity and 
duration of immunosuppression, amount of lymphoid tissue present in the transplanted organ, 
EBV serostatus pretransplant, and, in the case of HSCT, depletion of T-cell donor cells from the 
graft (11).   
 The clinical presentation and pathology of PTLD is quite varied.  Symptoms include 
lympadenopathy, malaise, fever and sweats, and can resemble a primary infection of EBV.  The 
disease can present as a tumor localized to a specific area, often involving major organs, or can 
be a diffuse polyclonal lymphoproliferation.  While many histological classifications have been 
developed over the years, none has been widely accepted, and the disease continues to be 
described in various manners.  PTLDs can stem from a variety of EBV-infected B cells, 
including naïve, memory, and germinal center (153).  Most often, a Latency III type profile is 
expressed, but Latency I & II have also been documented.  In some PTLDs, atypical crippled 
germinal center cells with no surface expression of immunoglobulin have been detected, as in 
Hodgkin’s Disease.  Such cells have crippling or destructive mutations in the Ig locus (80).   
Because of the wide range of nonspecific symptoms, and because early detection is 
vitally important for survival, specific methods to detect early signs of PTLD are imperative.  
One of the most commonly used is viral load monitoring.  PTLD is nearly always associated 
with a sharp rise in EBV viral load in the peripheral blood, which can easily be detected by 
polymerase chain reaction (PCR) (126, 143, 156, 157).  A caveat to this method is that nearly 
half of transplant recipients carry a stable elevated viral load in their peripheral blood, even 
without looming PTLD (see below).  A schedule of regular testing for changes in viral load is 
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 therefore important to distinguish between a chronically high load and one that is rising in 
advance of symptomatic PTLD (127).  Further, assays to enumerate the CTLs specific for EBV 
in the peripheral blood of transplant recipients is useful in determining the risk of PTLD (24, 98).   
 Treatment protocols for PTLD are diverse and nonstandardized.  A summary of various 
strategies for both solid organ and hematopoietic stem cell transplantation is shown in Table 2 
(53).  Boosting of the immune response to restore the balance between virus and immune control 
has been the main focus of disease treatment protocols.  This principle is outlined in Figure 3 
(53).  Withdrawal or reduction of immune suppression has been the first step in solid organ 
transplant recipients.  However, with the reduction of immunosuppression, the risk of allograft 
rejection rises, and careful monitoring must be conducted.  For HSCT recipients, treatment with 
interferon-alpha and adoptive immunotherapy with donor T cells and/or EBV-specific CTLs 
derived from the donor has been the regimen.  Another approach in both types of transplants, is 
to eliminate CD20+ B cells with the chimeric mouse/human monoclonal antibody, rituximab 
(38, 79, 102).  While this treatment is effective in decreasing viral load by eliminating the viral 
reservoir, CD20 negative PTLDs have been reported, and the possibility of recurrence is high, 
once the B-cell pool is regenerated (158).  Chemotherapy has also been utilized, but has been 
associated with high mortality rates.  If the lymphoma is localized, radiation or surgery to 
remove the tumor is a possibility.  Usually such localized approaches are in conjunction with 
systemic treatments, so the efficacy of localized approaches alone has not been proven. 
 Perhaps the treatment approach that holds the most promise is cellular immunotherapy.  
For HSCT recipients, antigen-specific CTL lines have been generated from the seropositive 
donors, using LCLs derived from donor B cells as targets (15, 67, 125).  This technique has 
several advantages, stemming mainly from the fact that the PTLDs are mainly of donor origin 
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 and express the highly immunogenic EBV antigens.  In clinical trials, the disease has readily 
responded to donor-derived EBV-specific CTL infusions.  In solid organ transplant recipients, 
the donor and recipient are typically not HLA-matched and the tumor cells are typically of 
recipient origin, so donor-derived CTL lines are not a therapeutic option.  Autologous CTLs are 
often not available because many recipients are EBV negative at the time of transplant, and 
ongoing immunosuppression quickly eliminates the EBV-specific CTLs.  In addition, time is a 
factor and, the generation of such CTLs is time consuming.  A possibility for future treatments 
lies in the development of a bank of allogeneic CTL specific for EBV, which would be 
immediately available after cross-matching with patients’ B cells (133, 146).  A reduction of 
immunosuppression is still necessary.  Despite the advances in treatment regimens, EBV-
associated malignancies still remain life-threatening.  The experience of immunosuppressed 
patients with EBV infections exposes the necessity for constant surveillance by a healthy 
immune system in order to maintain the precarious balance between virus and host.   
18 
 Table 2. Strategies of PTLD treatment.  
 
Transplant Type Treatment 
Reduction of immunosuppression 
Interferon-alpha 
CD20 antibody (Rituximab) 
Surgery/radiation/chemotherapy 
IL-6 
Antiviral agents 
Solid Organ 
Transplantation 
EBV-specific CTL 
CD20 antibody (Rituximab) 
Donor T-cell infusion Hematopoietic Stem Cell Transplant 
EBV-specific CTL 
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Figure 3. The principle driving treatment for PTLDs (53).  
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 1.5. VACCINE STRATEGIES 
 
While in the vast majority of individuals EBV is a harmless passenger, easily controlled by the 
body’s immune system, in some individuals EBV drives a broad range of diseases than can cause 
significant morbidity and mortality.  Therefore, a prophylactic vaccine that would not prevent 
primary infection, but prevent the acute disease associated with persistent infection would be 
most beneficial (123).  Using the humoral immune approach, vaccines expressing the major viral 
envelope protein, gp350 have been developed with mixed results (56, 68, 150).  Most recently, a 
live recombinant vaccinia vaccine expressing gp350 provided protection in two-thirds of 
vaccinated infants.  Other attempts at therapeutic vaccines have been developed based on direct 
peptide immunization approaches.  Immunodominant HLA Class I and II epitopes from LMP2, 
LMP1, and EBNA1 have been used in an effort to create a strong and sustained T cell response  
(106).  Such efforts are ongoing, but have seen some success, primarily in reactivating  CD4+ 
and CD8+ cells in vitro.  Perhaps the best approach would be to combine both to elicit both 
neutralizing antibodies and cellular immunity. 
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 2. SPECIFIC AIMS 
 
Although 90% of the world’s population is infected with EBV, the typical immunocompetent 
host has no symptoms of the infection and carries the virus benignly for life.  However, in 
immunosuppressed individuals, EBV has greater pathogenic potential and has been implicated in 
a number of disease states.  One group at risk for the development of EBV-induced 
lymphoproliferative disease is pediatric solid organ transplant recipients who are undergoing an 
immunosuppressive drug regimen.  Individuals with posttransplant lymphoproliferative disease 
(PTLD) have been shown to harbor levels of virus in their peripheral blood at orders of 
magnitude 3-4 times that of a normal immunocompetent individual.  Furthermore, a large 
percentage of posttransplant pediatric solid organ recipients carry persistent abnormally high 
levels of viral load, in the absence of overt disease.  Our lab has previously identified two groups 
of such individuals, and characterized them as low load carriers (LLC) and high load carriers 
(HLC) (1).  
 Previously in our lab, the virus positive cells in patient blood samples were initially 
characterized by the direct visualization using fluorescent in situ nucleic acid hybridization 
(FISH).  Rose (2) began to characterize the cells of low load and high load carriers as being 
either low copy number cells (1-2 EBV genome copies/virus infected cell) or high copy number 
cells (10 or greater EBV copies/virus infected cell) with this technique.  Low load patients had a 
strong predominance of low copy number cells; high load patients also had low copy number 
cells, but carried the bulk of their increased viral load in a distinct population of high copy 
number cells.  We believe these high copy cells to stem from a different developmental process 
than the low copy cells, and will demonstrate different viral and cellular characteristics. The 
hypothesis of this proposal is that high load patients carry the bulk of their elevated EBV load in 
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 a distinct population of high copy cells that have a phenotype previously thought to be 
incompatible with survival in vivo.   
 
While high load carriers do not show overt symptoms of PTLD, their risk for the development of 
this potentially fatal disease could be increased by the presence of aberrant, EBV+ B cells in 
their peripheral blood.  With an extensive characterization of these cells, we have further 
determined the compartmentalization of the viral load and to determine if the typical high copy 
cell has a unique phenotype that has previously been undescribed.  We also determined the 
extent of the viral burden in such aberrant cells.  To this end, the following specific aims were 
proposed and completed: 
 
Specific Aims: 
1. Characterize the surface immunoglobulin  (sIg) status of virus infected B cells from 
high and low load carriers.  Since high and low load carriers have been shown to carry 
their viral burden in different manners, the infected cells were further characterized.  To 
achieve this, the surface immunoglobulin status of infected B cells from the peripheral 
blood of high and low load carriers was examined.  It was determined if the high copy 
cells share a common isotype and if this differs from the low copy cells.  CD19+ cells 
were examined by a conjunctive FISH/immunofluorescense procedure for the presence of 
both the viral genome and surface IgA, IgG, and IgM.   
 
2. Determine the frequency of Ig-null cells in high and low load carriers, as well as 
individuals with no detectable viral load.  To survive a germinal center reaction and 
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 circulate in the peripheral blood, B cells must typically receive two survival signals.  One 
of these is provided by the somatically mutated Ig molecules, with productive 
rearrangements that enable high affinity binding with antigen.  The previous aim 
demonstrated the presence in the peripheral blood of CD19+, Ig-null cells.  This is an 
aberrant type B cell, and the frequency in which these cells were present in the peripheral 
blood of transplant recipients was determined .  To achieve this, peripheral blood 
mononuclear cells (PBMCs) were stained with CD19 and a pan sIg marker, and analyzed 
by flow cytometry.   
 
3. Identify cellular phenotype and viral compartmentalization of Ig-null cells.  To 
further identify the phenotype of high copy cells, surface markers of typical B-cell 
identity were examined by four-color flow cytometry in the high load patient population.  
These markers were HLA Class I, HLA Class II, Ki-67, CD20, CD27, CD5, CD40, 
CD10, CD38, CD23, and CD69.  Further, Ig-null cells were isolated from PBMCs of 
high load carriers by both a MoFLo and a FACS Aria and the viral burden in the Ig 
positive versus Ig-null compartment was determined by quantitative-competitive PCR.  
The Ig-null compartment was further broken down into CD20 positive and negative, and 
HLA Class I positive and negative to see if there was further compartmentalization of the 
viral load.   
 
In collaboration with Children’s Hospital of Pittsburgh, we have access to a unique study 
population.  Transplant recipients without PTLD, but yet with chronic elevated viral loads in 
their peripheral blood, have proven to be a valuable resource for the characterization of EBV-
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 infected B cells.  Collectively, the studies presented here show that in this population, a large 
proportion of the EBV load is carried in an aberrant B cell that was previously believed to not be 
compatible with survival in vivo.  While much progress has been made concerning the 
pathogenesis of EBV, this study shows that in immunosuppressed individuals, the story may be 
much more complicated.   
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 3.1.1. Preface 
 
To further characterize Epstein-Barr viral infected cells in the peripheral blood of pediatric solid 
organ transplant recipients, we endeavored to determine the surface immunoglobulin status of 
the infected cells of both high and low load carriers.  The results were both novel and 
unexpected.  After peer-review, our manuscript was accepted and published in an American 
Society of Microbiology journal.  
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 3.1.2. Abstract 
 
Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, normally causes an asymptomatic 
latent infection with very low levels of circulating virus in the peripheral blood of infected 
individuals.  However, EBV does have pathogenic potential, and has been linked to several 
diseases, including posttransplant lymphoproliferative disease (PTLD), which involves very high 
circulating viral loads.  As a consequence of immunosuppression associated with transplantation, 
children in particular are at risk for PTLD.  Even in the absence of symptoms of PTLD, very 
high viral loads are often observed in these patients.  EBV-infected B cells in the circulation of 
16 asymptomatic pediatric solid organ transplant recipients from Children’s Hospital of 
Pittsburgh were simultaneously characterized for surface immunoglobulin (sIg) isotype and EBV 
genome copy number. Patients were characterized as high load and low load based on their 
stable level of circulating virus.  High load patients had both high and low copy cells. Cells with 
a high numbers of viral episomes (>20/cell) were predominantly Ig-null and cells with low 
numbers of episomes were predominantly sIgM positive. Low load patients carried the vast 
majority of their viral load in low copy cells, which were predominantly IgM positive. The very 
rare high copy cells detected in low load carriers were also predominantly Ig-null cells.   This 
suggests that two distinct types of B lineage cells contribute to viral load in transplant recipients, 
with cells bearing high genome copy numbers having an aberrant Ig-null cellular phenotype.   
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 3.1.3. Introduction 
 
Epstein-Barr virus (EBV) is a member of the gammaherpesviridae family.  Its genes are encoded 
in a 172 kb dsDNA molecule, and like other gammaherpesviruses, it has a very narrow host 
range and produces persistent infections in the lymphoid cells of the host.  EBV has a tropism for 
human B cells. The virus is primarily spread via intimate contact, but it is also transmissible by 
bone marrow engraftment, blood transfusion, or along with a donor organ during solid organ 
transplantation. Because of the efficient transmission of the virus via person-to-person contact, 
more than 90% of the world’s population is infected with EBV by adulthood (25).  
  Despite the high prevalence of EBV infection, only very rarely does EBV cause overt 
disease.  Most primary infections occur in childhood and are asymptomatic or exhibit only minor 
clinical symptoms. In adolescence and adulthood, primary EBV infection can manifest as 
infectious mononucleosis (11).  In an immunocompetent host, a primary infection with EBV is 
readily resolved by cytotoxic T cell-mediated immunity, but the host remains asymptomatically 
infected with the virus for life.  The virus has pathogenic potential in certain settings and 
associated disease states include oral hairy leukoplakia, nasopharyngeal carcinoma, EBV-
associated Burkitt’s lymphoma, Hodgkin’s lymphoma, and lymphoproliferative disease in 
immunocompromised patients. EBV-associated posttransplant lymphoproliferative disease 
(PTLD) in solid organ transplant recipients is a particular concern. Following organ 
transplantation, patients typically undergo an immunosuppressive drug regimen to prevent 
rejection of the donor organ.  As a result of this immunosuppression, immune responses that 
control EBV-driven B cell proliferation are reduced. PTLD can have a varied clinical 
presentation, ranging from posttransplant infectious mononucleosis to malignancies containing 
chromosomal abnormalities (22), and can range from localized lesions to disseminated 
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 involvement of the whole lymphoid system (24).  General risk factors for the development of 
PTLD include a primary EBV infection posttransplant, cytomegalovirus (CMV) status mismatch 
of the donor and recipient, CMV disease, type and intensity of immunsuppression (22), and the 
type of solid organ transplanted (19).    
 EBV-driven PTLD is an important cause of morbidity and mortality in the solid organ 
transplant recipient, especially in pediatric patients.  Estimates of the incidence of disease range 
from 0.7% (19) to 32% (7) in various allograft recipients, depending on a number of factors.  
From a large number of separate studies, it has been shown that the diagnosis of PTLD is also 
associated with a very high load of EBV in the peripheral blood (>1000 copies/ 105 peripheral 
blood mononuclear cells [PBMCs]) (6, 8, 9, 10, 15, 17, 18, 23, 26, 29, 31, 32, 35).  While normal 
immunocompetent adults harbor an average of approximately 0.01-0.1 genomes per 105 PBMCs 
(29), PTLD patients typically have viral loads several orders of magnitude greater at the time of 
their diagnosis. Before the symptoms of PTLD appear, there is a period of 2-6 weeks during 
which the EBV load in the peripheral blood is readily detected and rising.  This increase is 
usually detected by quantitative PCR.    Upon resolution of their symptomatic PTLD, patients 
often retain a much higher (by 2-3 orders of magnitude) circulating persistent viral load than a 
normal latently infected individual. In addition, persistently high viral load has been observed in 
a substantial percentage of pediatric solid organ transplant recipients who have never had a 
diagnosis of PTLD.  This persistently elevated load has generally been attributed to the 
immunosuppressive drug regimen that is administered to prevent rejection of the transplanted 
organ (36).  Serial monitoring with quantitative PCR reveals that many of these patients harbor 
persistently elevated viral loads asymptomatically for months to years (unpublished 
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 observations, 10, 15, 28, 34, 37, 38).  The potential complications arising from a very high viral 
load without overt disease have never been elucidated. 
 The chronic carrier states exhibited by the immunosuppressed pediatric solid organ 
transplant recipient population offer a unique opportunity to study viral latency and risks for 
development of PTLD.  Previously it has been shown that the latent EBV load is carried in the 
resting memory B cell (CD 19+, IgD-, Ki67-, CD 23-, CD 80-) compartment in the peripheral 
blood, in both immunosuppressed and immunocompetent persons (1, 2, 27).   Further studies 
have pinpointed latency to the CD27+, CD 5- B2 memory type of B cell in the peripheral blood 
of immunocompetent individuals (34). Immunosuppressed individuals also carry their chronic 
viral load in the memory B cell compartment of the peripheral blood (2, 27).  A preliminary 
analysis of EBV infected peripheral blood B cells by fluorescent in situ hybridization (FISH) for 
EBV DNA found that the distribution of the viral genomes in infected cell was related to the 
level of the patient’s viral load (28). In low load patients, cells had just one or two genomes per 
nucleus, while high load patients carried a large portion of their load in cells harboring as many 
as 20-50 genomes per cell (Figure 4). Increases in load were accompanied by an increase in the 
number of these high copy cells. Since high copy cells (greater than 10 genomes/cell) were found 
predominantly in high load patients, these cells were a distinctive marker for this group of 
patients. In terms of pathogenic processes, the high genome copy cells likely arise in a different 
manner from the low genome copy number cells. High copy cells warrant further analysis 
because they may be a key to understanding the development of at least some PTLDs.  Recent 
evidence suggests that the existence of aberrant cell types may be a main constituent in PTLDs 
and Hodgkin’s Disease lymphomas (14, 16, 33).  The characterization of the immunoglobulin 
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 phenotypes of EBV infected cells in high and low load asymptomatic carriers that is reported 
here lends support to this notion.   
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Figure 4a. EBV genome distribution per infected cell in low load patients.   
Summary of the EBV copy number in infected peripheral blood B cells, expressed as a 
percentage of all EBV-positive cells present and determined by fluorescent in situ hybridization. 
 
Figure 4b. EBV genome distribution per infected cell in high load patients. 
Summary of the EBV copy number in infected peripheral blood B cells, expressed as a 
percentage of all EBV-positive cells present and determined by fluorescent in situ hybridization. 
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 3.1.4. Materials and Methods 
 
Study Population: Since 1995, transplant recipients attending Children's Hospital of 
Pittsburgh (CHP) and University of Pittsburgh Medical Center have been regularly monitored for 
EBV viral load using a quantitative-competitive PCR (QC-PCR) protocol developed in our 
laboratory (10). We have followed bowel, liver, lung, renal and heart transplant recipients for 
EBV-DNA copy number in peripheral blood lymphocytes. We have focused on the pediatric 
transplant population because within this group there are more than 190 patients for whom we 
have multiple prospectively collected specimens. In only 34.2% of these patients (34.2%) has 
there never been a detectable viral load. A chronic “low” load (defined as detectable but < 200 
genome copies/105 lymphocytes for > two months) has been detected in 36.3% of patients and a 
chronic ‘high’ load (defined as >200 genome copies/105 lymphocytes for > two months) 18.4%. 
The remaining 11.1% of patients have had viral loads that have fluctuated. As the lower limit of 
the QC-PCR test is 8 genome copies per 105 lymphocytes (29), normal latent infection is not 
detected by this assay; thus, the detected loads must be at least 2-3 orders of magnitude greater 
than normal latency.  This research has complied with all relevant federal guidelines and is 
covered by CHP Human rights Committee research protocol # 00-155.  
Quantitative-competitive (QC)-PCR of EBV loads:  Lymphocytes were prepared from 
whole blood samples by centrifugation onto a histopaque (Sigma-Aldrich, St. Louis, MI) 
cushion. The cells were washed in phosphate buffered saline (PBS) and counted. Cell pellets 
were stored at –20 C until ready for PCR. Plasma volume equivalent to 4 x 105 cells for each 
patient was ultracentrifuged at 14000 rpm for 90 min in order to pellet cell-free virus. To make 
lymphocyte and plasma lysates 20µl of PCR lysis buffer (50 mM KCL, 10 mM Tris [pH 7.6], 2.5 
mM MgCl2, 1% Tween 20, and 100µg of proteinase K per ml) was added for every 105 
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 lymphocytes or plasma volume equivalents. The lysates were incubated at 55ΕC for 1 hr, boiled 
for 10 min to inactivate the proteinase K and chilled on ice. Primers for the PCR target sequence 
in the EBV genome were designed with OLIGO software (National Biosciences Inc., Plymouth, 
MN). TP1Q5' (AGGAACGTGAATCTAATGAAGA) and TP1Q3' ( 
GAGTCATCCCGTGGAGAGTA) amplify a 177-bp EBV sequence (exon 1) in the lmp2a gene. 
A competitor target was made by deleting 42-bp from a 177-bp EBV amplicon derive from the 
viral lmp2a exon 1 sequence. For each sample, four tubes containing 8, 40, 200 or 1000 copies of 
the viral LMP2a competitor sequence along with lymphocyte or plasma lysates equivalent to 105 
cells were subjected to 30 cycles of amplification (94ΕC for 1 min, 54ΕC for 1 min and 72 ΕC 
for 1 min). Each PCR reaction (50µl) contained 20 pmol of 5' and 3' primers,  50mM  KCL, 2.5 
mM MgCl2, 10 mM Tris [pH 9.0], 0.1 % Triton X-100, and 0.25 mM deoxynucleotides (Pfizer, 
New York, New York). One unit of Amplitaq Gold DNA polymerase (Perkin Elmer, Wellesly, 
MA) was used in each reaction. The PCR products were analyzed on 3% agarose gels containing 
0.5X Tris-borate-EDTA electrophoresis buffer and 0.5µg of ethidium bromide per ml.   
 The QC-PCR assay for EBV is used to quantitate viral loads in the range of 8 to 5000 
copies of viral DNA in 105 lymphocytes. Normal latent infection (0.01 - 0.1 copies/105 
lymphocytes) is not detected by this protocol and detectable levels of viral DNA reflect a viral 
genome burden at least 2 to 3 orders of magnitude above normal latency. 
Cell Sorting with magnetic Beads: Lymphocytes were positively sorted for CD19+  B cells by 
using MACS CD19 Microbeads (Miltenyi Biotech, Auburn, CA). Histopaque lymphocyte 
preparations from patient blood samples were mixed with 20ul of CD19 Microbeads per 107 total 
cells and incubated for 15 minutes at 4ΕC . The cells were washed and magnetically separated 
using a positive selection LS column. The retained CD19+ cells were eluted with MACS buffer, 
49 
 spun onto Superfrost Plus glass slides (Fisher Scientific, Hampton, NH) with a Shandon 
Cytospin 3 (Thermo Electron Corporation, Waltham, MA) at 500 rpm for 5 minutes.  Namalwa 
cells, a Burkitt Lymphoma cell line that contains two integrated copies of the EBV genome were 
also spun onto the same slide to be used as a control in the in situ hybridization reaction.  Purity 
of the CD19+ population ranged from 95-80%,in a control sample of PBMC’s, as confirmed by 
flow cytometry.  
Construction of DNA Probe:  The double-stranded EBV-specific DNA probe was made 
from the plasmid p1040, containing a cloned Bam HI WWYH fragment of the EBV strain B95-
8.  The 14.7 kb fragment was cloned into a holding vector and linearized with HindIII.  The cut 
DNA was purified from the agarose gel with the MinElute Gel Extraction Kit (Qiagen Inc., 
Valencia, CA), and double-stranded EBV DNA probes of 250-300 bp were generated with the 
Prime-A-Gene Labeling System (Promega, Madison, WI) and labeled with digoxigenin-11 
(DIG)-2’-dUTP (Roche, Basel, Switzerland) at room temperature overnight.  To terminate the 
reaction, the mixture was heated to 95ºC for two minutes, followed by chilling in an ice bath.  
20mM EDTA was added, followed by a standard phenol-chloroform extraction of the probe.  
The purified probe was stored at –20ºC until direct use in the in situ hybridization reaction.  
In Situ Hybridization: Fluorescent in situ hybridization (FISH) was performed on CD19+ 
cells from patient peripheral blood samples.  The slides were fixed in methanol:acetic acid (3:1) 
at room temperature for 15 minutes.  After washing twice with 1X PBS, slides were aged in 2X 
SSC at 37ºC for 30 minutes, followed by dehydration in an increasing ethanol series. The slides 
were prewarmed and denatured in a 70% formamide-2X SSC solution for 2 minutes and 
immediately placed in cold graded series of ethanol for 5 minutes each.  For each sample,50 ng 
of probe, 5 µg of salmon sperm DNA, and 20 µg of yeast tRNA were suspended in a solution of 
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 50% formamide, 10% dextran sulfate, and 1X SSC.  This hybridization mixture was heated to 
80ºC for 10 minutes, followed by a preannealing at 37ºC for 15 minutes.  After prewarming the 
slides at 37ºC, 30 ul of the hybridization was added to each sample for a 37ºC overnight 
incubation.  The following day, the slides were washed in a 50% formamide-2X SSC solution for 
30 minutes at 37ºC, followed by a 30 minute was in 2X SSC at 37ºC.  The slides were treated 
with RNase H (8 U of RNase H/ml in RNase H reaction buffer) for 1 hour, also at 37ºC.  The 
slides were then washed twice with 2X SSC. 
Immunofluorescence (IF): Surface immunoglobulin expression was detected with fluorescein 
(FITC)-conjugated monoclonal antibodies against surface IgM, IgA, and IgG (Biosource 
International, Camarillo, CA).  Blocked slides were incubated for 30 minutes at room 
temperature with their respective antibody at a 1:250 dilution.  They were then washed twice 
with 1X PBS.  A cell was either scored positive or negative based on the expression level of 
surface immunoglobulin.   
Immunological Detection of EBV probe: To detect the bound DIG-labeled EBV probe, the 
blocked slides were incubated with anti-DIG-rhodamine-Fab fragments (Roche, Basel, 
Switzerland) for 30 minutes at room temperature.  The slides were washed twice with 1X PBS, 
dried, mounted with Vectashield mounting media plus 4’,6’-diamidono-2-phenylindole (DAPI) 
(Vector Laboratories, Burmingdale, CA), and sealed.  A positive signal is characterized by a red 
dot, with a surface area of approximately 22 pixels in the DAPI-stained nucleus (blue).  Each 
specific signal represents one EBV genome, although some genomes may be closely spatially 
related and are visualized as one larger signal. 
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 Photomicroscopy: The sealed slides were examined under a Nikon E600 microscope 
equipped with a SPOTII charge-coupled device digital camera.  Images of cells were generated 
and analyzed with Metamorph software (Universal Imaging, Westchester, PA).   
 
3.1.5. Results 
 
3.1.5.1. Surface Isotype Expression in CD19+ Cells 
 
Immunofluorescence for surface expression of the IgM, IgA, and IgG isotypes was conducted on 
CD19+ cells that had been positively sorted from the PBMCs of children who have undergone 
solid organ transplantation at Children’s Hospital of Pittsburgh. Eight high and eight low load 
patients (as defined in the Materials and Methods) were selected for this study (Table 3a and 3b).   
Detection of surface expression of IgD was not performed, since we and others have previously 
shown by polymerase chain reaction that persistent infection with EBV does not involve the 
naïve IgD+ B cells of both normal and immunosuppressed individuals (1, 2, 12, 20, 27).  IgM, 
IgA, and IgG positive cells were observed in all patient samples (Figure 5). Similar numbers of 
IgG expressing cells were observed in both the high and low load patients (3.4% for high load 
patients vs 2.6% for low load patients).  There were slightly more IgA+ cells in the high load 
patients (3.6% in high load patients and 2.1% in low load patients), although this average was 
skewed by the unusually high percent (20%) of IgA+ virus-infected cell in one high load patient 
(pt 2).  When pt. 2 is removed, the percent of IgA+ cells in high load patients is comparable to 
the percent of IgA+ cells in low load patients. Low load patients had substantially more IgM+ 
cells than the high load patients (87.2% for low load patients vs 62.3% for high load patients), 
while the high load patients had substantially more cells with no detectable immunoglobulin  (Ig) 
52 
 isotype compared to the low load patients (30.8% of high load patients vs 9.0% of low load 
patients).  Some of the Ig-null cells observed may be attributed to the sorting procedure, in which 
it is inevitable that a small percentage (5-10%) of CD19- cells will remain after the sort.  In 
addition, in an ongoing study, high load patients were shown to have a substantially higher 
number of Ig-null cells, as determined by flow cytometry. 
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 Table 3a. Summary of High Load Patient Population 
 
 
Patient 
number 
Sex History 
of PTLD 
Age (mo) 
at 
transplant 
Mo. Post-
transplant 
of 
specimen 
EBV status 
pretransplant 
Type of 
transplant  
EBV load 
(no. of 
copies/10^5 
PBLs) 
1 F No 10 12 Neg Liver 5000 
2 M No 15 25 Neg Liver 2500 
3 F Yes 8 16 Neg Liver 2500 
4 F Yes 19 21 Neg Heart 2000 
5 M No 44 21 Neg Liver 500 
6 F No 6 56 Neg Heart 500 
7 M Yes 120 80 Neg Kidney 200 
8 F No 125 6 Neg Double 
Lung 
200 
 
Table 3b. Summary of Low Load Patient Population 
 
 
Patient 
number 
Sex History 
of PTLD 
Age (mo) 
at 
transplant 
Mo. Post-
transplant 
of 
EBV status 
pretransplant 
Type of 
transplant  
EBV load 
(no. of 
copies/10^5 
1 F Yes 72 70 Neg Liver 100 
2 M No 152 3 Neg Kidney 100 
3 F No 22 41 Neg Liver 80 
4 M Yes 61 67 Neg Liver 40 
5 M No 2 37 Pos Liver 20 
6 M No 118 86 Unknown Kidney 20 
7 M Yes 83 156 Unknown Multi-
visceral 
8 
8 M No 100 28 Pos Kidney 8 
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Figure 5. Distribution of isotypes in CD19+ cells of high and low load patients. 
The percentage of surface IgA+ (A and B), IgM+ (C and D), and IgG+ (E and F) peripheral 
blood B cells was determined in chronic high (A,C, E, and G)and low (B, D, F, and H) load 
patients with FISH and immunofluorescence, and expressed as a percentage of all CD 19+ cells 
present. The percentage of cells in which no surface immunoglobulin was detected is shown in G 
and H.   In each graph, high load patients 1-8 (left side of the figure) are shown left to right, as 
are the low load patients 1-8 (right side of figure). 
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 3.1.5.2. Surface Isotype Expression of Virus-Infected Cells in Patients with Low Viral 
Loads 
 
A combined FISH/IF procedure was used to generate an isotype profile for the EBV- infected 
cells in purified CD19+ cells from 8 low load patients (Figure 6).  Examples of cells for each 
isotype are shown in Figure 3.  Typically, low load carriers carry 1-2 viral genomes per infected 
B cell in the peripheral blood.  Cells with a greater copy number of EBV genomes are rare or 
undetectable.  The majority (85.5%) of the low copy cells from this patient group were IgM+. 
Low copy cells with IgA and IgG expression were also detected at a very low frequency (average 
IgA+ = 3.3%, average IgG+ = 1.0%).  For low load patients, an isotype for 10.3 % of low copy 
virus-infected cells was not identified using our FISH/IF procedure. High copy cells in this 
patient population are extremely rare. Two patients had no detectable high copy cells while the 
remaining 6 patients had, on average, only 1 or 2 high copy cells per slide of an estimated 
50,000-100,000 cells per slide.  Of these high copy cells, approximately 70% did not have 
detectable Ig isotype expression. In addition, there were no IgG+ high copy cells identified in 
any of the low load patients. One low load patient (pt # 5) had a small percentage of IgA+ high 
copy cells.  All other high copy cells detected were IgM+ (Figure 6).   
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Figure 6. Distribution of isotypes in virus-infected cells in eight low load patients.   
The percentage of EBV-positive, surface IgA+ (A and B), IgM+ (C and D), and IgG+ (E and F) 
high (A, C, E, and G) and low (B, D, F, and H) copy cells in the peripheral blood B cells of 
persistent low load carriers was determined with FISH and IF and expressed as a percentage of 
high and low copy cells detected.  The percentage of infected cells in which no surface 
immunoglobulin was detected is shown in G and H.  For each graph, low load patients 1-8 are 
represented left to right. 
57 
 3.1.5.3. Surface Isotype Expression of Virus-Infected Cells in Patients with High Viral 
Loads 
 
The FISH/IF procedure was applied to positively sorted CD 19+ cells from the peripheral blood 
of 8 high load patients. Examples of both positive and negative surface Ig isotype expression in 
virus infected cells are shown in Figure 7.  Virus-infected cells with low numbers of viral 
genomes were present in all patients, and these cells were predominately IgM+ (67.2%) (Figure 
7).  IgA+ and IgG+ low copy cells were also observed at lower frequencies, in some high load 
patients (Figure 7).  All high load patients carried high copy cells (at an average of 86 high copy 
cells per slide) in all high load carriers and most of these cells (68.0%) had no detectable surface 
Ig isotype expression.  A significant difference (p<0.05) in the number of high copy cells per 
slide existed between the high and low load patients.  Several of the high load patients showed 
no sIg expression on up to 85% of their high copy cells. Of the high copy cells with detectable 
surface Ig expression, 45.7% were IgM+, 31.7% were IgA+, and 22.6% were IgG+.   
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Figure 7. EBV genomes and surface immunoglobulin expression.   
Representative EBV+ and surface Ig+ cells are shown, as detected by FISH and IF.  The top 
panels represent virus positive high copy cells, without surface expression of Ig, with an IgM+ 
(left), IgA+ (middle), and IgG+ (right) cell nearby.  The middle panels represent double positive 
high copy cells, with multiple copies of the virus, and surface expression of IgM (left), IgA 
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 (middle), and IgG (right).  The bottom panels represent virus positive low copy cells, with a 
single viral genome present in an IgM+ (left) and IgA+ (middle) cell.  The bottom right panel 
represents a low copy cell with no surface Ig expression next to an IgG+ cell.  For each panel, 
red is the viral genome, blue is the nucleus, and green is the surface immunoglobulin expression. 
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Figure 8. Distribution of isotypes in virus-infected cells of high load patients.   
The percentage of EBV-positive, surface IgA+ (A and B), IgM+ (C and D), and IgG+ (E and F) 
high (A, C, E, and G) and low (B, D, F, and H) copy cells in the peripheral blood B cells of 
persistent high load carriers was determined with FISH and IF and expressed as a percentage of 
high and low copy cells detected.  The percentage of infected cells in which no surface 
immunoglobulin was detected is shown in G and H.  For each graph, high load patients are 
represented left to right. 
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 3.1.6. Discussion 
 
Previously, we have reported that children who undergo solid organ transplantation often carry 
persistently elevated viral loads of EBV in their peripheral blood.  Upon direct examination of 
the virus infected B cells from the peripheral blood by fluorescent in situ hybridization, we 
determined that patients with loads of <200 copies/105 lymphocytes, infected cells had 1 to 2 
copies of the viral genome per nucleus (low copy cells). High load patients (>200 copies/105 
lymphocytes) had these low copy cells, but also had another population of virus infected cells 
with 20-50 genomes per nucleus (high copy cells) (28). In a larger pediatric transplant 
population, we have now characterized the two types of virus-infected cells for surface 
immunoglobulin isotype. 
 In our study we used fluorescent probes to directly visualize the infected cells and 
simultaneously determine the surface Ig phenotype and viral genome copy number of individual 
infected cells. For the patients in our study, the proportion of peripheral blood B cells with sIgM, 
sIgG or sIgA was within the normal range for children. In both low and high load patients, the 
EBV infected cells with low genome copy number had mainly IgM B cell receptors.  Previous 
work had shown that for both immunocompetent and immunosupressed individuals, the EBV 
latent load was carried in what appeared to be the resting memory B cell compartment (CD19+, 
IgD-, Ki67-, CD23-, CD80-) (1, 2, 27).  The current study indicates that for the pediatric 
transplant population, these virus-infected cells carry low number of EBV episomes and are 
IgM-positive. The implication therefore is that they do not appear to have undergone isotype 
switching after EBV infection.  They do not necessarily have to have arisen from a population of 
cells participating in germinal center reactions within the lymph nodes.   
62 
 As in our previous studies on pediatric transplant recipients, high copy cells were a 
distinctive feature of patients carrying high viral loads and were responsible for high circulating 
loads at the time of PTLD diagnoses (28).  Unexpectedly, the characterization of the Ig isotype 
of the B cell receptors (BCRs) on these cells revealed that the majority of these cells had no 
detectable surface Ig expression. Internal controls demonstrated that this was not a technical 
problem in detection of surface Ig in these experiments. IgM+, IgA+, and IgG+ cells were 
observed on all slides and the frequency of the different isotypes in the circulating B cell pool 
was within the expected range. Some high genome copy cells did express sIg. For these, the 
frequency with which the virus appeared in B cell of different isotypes was not the same as the 
frequency of these isotypes in the circulating B cell population. The IgG isotype was 
underrepresented and the IgA isotype was overrepresented in the virus-infected sub-popoulation. 
The simplest explanation for the origin of high copy null cells would be that after infection of 
mature naïve B cells, the cells proliferated (increasing the copy number of viral genomes per 
cell) and then attempted to make an isotype switch. When an isotype switch was productive, it 
led more often to IgA expression. It would appear, however, that most of the switch attempts 
were unsuccessful, leading to the Ig-null cell phenotype. 
Since B cells require a functional surface antigen receptor to receive survival signals 
throughout the lifetime of the cell, Ig-null cells are normally incompatible with survival in vivo. 
They would be expected to be rapidly eliminated, and not permitted to enter or persist in the 
circulation.  The persistence in the peripheral blood of B cells with no detectable Ig expression 
suggests that these cells may be receiving an abnormal survival signal, most likely provided by 
EBV. The high copy cells are in this respect atypical B cells. It is possible that these cells have 
survived germinal center reactions which produced unsuccessful Ig affinity maturation and/or 
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 isotype switching. Ig-null cells have recently been described in EBV-infected B cells in 
angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) (6), EBV-positive 
Hodgkin’s Disease (14, 16), and in the B cells of EBV-positive post-transplant 
lymphoproliferative disease (3, 33). Lack of CD20 and surface immunoglobulin light-chain 
expression was also observed in various PTLD lesions by flow cytometry (13).  These latter 
studies have led researchers to suggest that EBV interferes with the normal B cell differentiation 
and selection processes in PTLD (3).  The Ig-null phenotype of high copy EBV infected B cells 
in asymptomatic children with solid organ transplants suggests that such interference is not 
confined to the disease state and that high load carriers, in particular, show signs of aberrant B 
cell development and may be at risk for further EBV-driven complications.  
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 3.2.1. Preface 
 
Based on the previous results that high copy cells in pediatric solid organ transplant recipients 
have an aberrant Ig-null phenotype, further studies were needed.  In this study, we further 
characterized these cells by phenotyping them and determining the compartmentalization of viral 
load.  This manuscript is being prepared for submission to an American Society of Microbiology 
journal, the Journal of Clinical Microbiology for peer review.   
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 3.2.2. Abstract 
 
Epstein-Barr virus (EBV) causes an asymptomatic latent infection with very low levels of 
circulating virus in the peripheral blood of most adults.  However, EBV does have pathogenic 
potential, and has been linked to several diseases, including posttransplant lymphoproliferative 
disease (PTLD), which can involve very high circulating viral loads in the peripheral blood.  As 
a consequence of immunosuppression associated with transplantation and serostatus pre-
transplant, children in particular are at risk for PTLD.  Even in the absence of symptoms of 
PTLD, very high viral loads are often observed in these patients.  Previously, we demonstrated 
the presence of infected B cells with high genome copies of EBV that showed no demonstrable 
surface immunoglobulin (Ig-null cells) in asymptomatic pediatric solid organ transplant 
recipients from Children’s Hospital of Pittsburgh (29).  In this study, we further examined Ig-null 
cells in the circulation of high load transplant recipients by four-color flow cytometry.  We 
demonstrated that Ig-null cells have the surface phenotype CD19+, sIg-, CD5-, CD10-, CD27-, 
CD23-, CD38-, CD69-, and Ki67-, with variable surface expression of CD20 and CD40, and 
HLA Class I and Class II.  Upon sorting of Ig-null and Ig positive cells, we saw that a significant 
fraction of the viral load is carried in the Ig-null compartment, with variation from patient to 
patient.  Further sorting of the Ig-null, CD20 +/- cells, and Ig-null HLA Class I +/- cells 
demonstrated the presence of virus in the double negative compartment, again with variation 
from patient to patient.  This suggests that high copy cells are an aberrant feature of EBV 
infection in these patients.  In some patients, the bulk of the viral load is carried in Ig-null cells.  
Ig-null cells have been linked to other EBV-associated disease states, suggesting that these 
patients may be at higher risk for complications. 
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 3.2.3. Introduction 
 
Epstein-Barr virus (EBV) is a ubiquitous gammaherpesvirus that establishes a persistent latent 
infection in the B lymphocyte compartment that is asymptomatic and lifelong in the vast 
majority of the human population (24).  Primary infections with EBV are nearly always 
asymptomatic in childhood, but can be manifested as infectious mononucleosis in adolescence 
and adulthood (24).  Despite this normally benign pathogenesis of EBV infection, it has been 
linked as the etiological agent to Burkitt’s lymphoma, Hodgkin’s Disease, and nasopharyngeal 
carcinoma.  Furthermore, upon suppression of T-cell mediated immunosurveillance, EBV 
infection can opportunistically be manifested as an oral hairy leukoplakia and/or a 
lymphoproliferative disease (24). In transplant recipients, EBV driven post-transplant 
lymphoproliferative disease (PTLD) poses a significant health threat.  General risk factors for 
this complication include type and intensity of immunosuppression, type of transplanted solid 
organ, EBV seronegativity pre-transplant, and presence of CMV disease (17, 21).  PTLDs can 
have a varied clinical presentation, ranging from a clinical syndrome clinically indistinguishable 
from infectious mononucleosis to malignancies with chromosomal abnormalities (21). The 
effects range from localized lesions to disseminated involvement of the lymphoid system (23).  
The morbidity and mortality attributable to EBV-associated PTLDs can be very high, with 
estimates of the incidence of this complication ranging from 1-20%, depending mostly on the 
type and intensity of immunosuppressive drugs and the type of organ transplanted (8).   
A very high load of EBV in the peripheral blood (>1000 copies/105 PBMCs) is strongly 
associated with a diagnosis of PTLD (5, 6, 8-11, 13, 15, 16, 22, 25, 28, 30, 31, 35).  This load is 
at least 2-3 orders of magnitude greater than the viral load measured in normal, 
immunocompetent individuals, and its rise can be detected by quantitative competitive 
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 polymerase chain reaction (QC-PCR) 2-6 weeks before patients present with physical symptoms 
of PTLD (32, 36).  After resolution of the PTLD, accomplished by a reduction of 
immunosuppression or antineoplastic chemotherapeutic treatment, a viral load is present in B 
cells in the peripheral blood at an elevated level for an extended period of time. Longitudinal 
studies have revealed that many pediatric solid organ transplant recipients develop a persistently 
elevated viral load in their peripheral blood, even in the absence of clinical signs or symptoms of 
PTLD (11, 13, 27, 34, 38, 39).  This load is generally attributed to the immunosuppressive drug 
regimen prescribed to prevent organ rejection in the patient (37).  Although the level of the load 
varies widely from patient to patient, our experience has led us to separate and characterize 
patients as belonging to one of two broad categories: being either high or low load carriers. High 
load carriers are defined as having a persistent asymptomatic viral load of >200 copies/105 
lymphocytes for at least two months, while low load carriers have persistent asymptomatic loads 
that range between 8 and <200 copies/105 lymphocytes for at least two months (27).   
By directly examining the EBV infected cells with fluorescent in situ hybridization 
(FISH), we have shown that a distinct population of B cells carrying large numbers of EBV 
genomes accounts for the elevated levels of virus in high load patients (27).  These High Copy 
Cells (HCCs) have >10 EBV genomes per cell and usually have 20 to 40 distinct FISH spots per 
nucleus.  Up to 30% of high load patients’ EBV infected cells are HCCs. The remainder of the 
virus infected cell population consists of Low Copy Cells (LCCs).  LCCs have 1-2 viral genome 
copies/nucleus; these cells appear to be the predominant carriers of viral load in low load 
transplant patients and normal healthy carriers. Less than 5% of infected cells in low load 
patients have 10 or more FISH spots per nucleus (27).  Further analysis of the infected cells for 
surface immunoglobulin expression with a combination FISH/immunofluorescence (IF) 
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 procedure, revealed that the majority of low copy cells were IgM+ in both high and low load 
patients (29).  Nearly 70% of HC cells in high load patients were Ig-null cells, with no 
discernable immunoglobulin expressed on their surface.  The very rare HCCs in low load 
patients showed a similar phenotype (29).  
 Ig-null cells have also been observed in other EBV-associated diseases.  
‘Crippled’ and ‘forbidden’ Ig- cells in angioimmunoblastic lymphadenopathy with 
dysproteinemia and in the Reed-Sternberg cells of classical Hodgkin’s Disease have been 
observed (3, 4, 12).  These latter cells have also been shown to have lost B-lineage-specific gene 
expression, adding to the aberrant nature of Ig-null cells (3).  In EBV-positive PTLD, cells that 
have failed the germinal center process, and thus should have been eliminated, were shown to 
play an integral part in development of lymphoproliferative disease. (33) Since Ig-null cells are 
an aberrant type of cell that should not survive in the peripheral blood and may lead to 
complications in the organ recipient, we have studied them further, determining the frequency of 
such cells in the peripheral blood of solid organ transplant recipients and examining their surface 
marker phenotype and contribution to persistent viral load.   
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 3.2.4. Materials and Methods 
 
Patient Population:  Since 1995, we have monitored children who have received solid organ 
transplants at Children’s Hospital of Pittsburgh for viral loads of Epstein-Barr in their peripheral 
blood by quantitative-competitive PCR.  This technique was developed in the Department of 
Infectious Diseases and Microbiology, Graduate School of Public Health, University of 
Pittsburgh (11).  We have multiple prospectively collected samples from nearly 200 patients who 
have had a bowel, liver, lung, renal, or heart transplant.  Of these, 34.2% have never had a viral 
load.  Slightly more than 36% have had a consistently detectable low load, defined as <200 viral 
genome copies /105 lymphocytes for >2 months.  Eighteen percent of the patients have been 
classified as having a persistent high load, defined as having a viral load >200 viral genomes/105 
lymphocytes for >2 months.  The remaining patients have had fluctuating viral loads.  The lower 
limit of the QC-PCR test is 8 genome copies per 105 lymphocytes; as such, the test does not 
detect a normal latent infection without purification of B cells.  For a viral load to be detected, 
the load must be 2-3 orders of magnitude greater than the level of viral load expected to be 
identified in a normal immunocompetent individual.   
Flow Cytometric Analysis of Ig-null cell number.  Peripheral blood mononuclear cells were 
prepared from whole blood specimens by centrifugation onto a Histopaque (Sigma) cushion.  
Cells were stained for two color analysis with CD19-PC7 (Beckman Coulter) and pan goat 
F(ab’)2 anti-human Ig’s-fluorescein isothiocyanate (sIg-FITC) (Biosource International).  Cells 
were incubated for 30 minutes at 4 degrees Celsius and fixed in 1% paraformaldehyde.  Isotype 
controls were IgG1-PE (Pharmingen) and preimmune goat F(ab’)2 IgG control-FITC (Biosource 
International), as well as unstained cells in some instances.  The cells were analyzed on a 
Beckman Coulter XL flow cytometer and analysis was done with Cytomation Summit v3.1.  Ten 
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 high load patients, ten low load patients, and 11 patients with a consistently undetectable viral 
load were examined.  The patients were picked as the first 10 high load, 10 low load, and 11 ND 
patients whose blood was available for study.   
Flow cytometric analysis of phenotype: Peripheral blood mononuclear cells from high load 
patients were prepared from whole blood specimens by centrifugation onto a Histopaque (Sigma) 
cushion.  For four color analysis, each set of cells was stained with CD19- PC7 (Beckman 
Coulter) and pan goat F(ab’)2 anti-human Ig’s-FITC (Biosource International), plus HLA Class 
I-PE (BD Pharmingen) and HLA Class II-PC5 (Immunotech), or CD27-PE (Immunotech) and 
CD20-PC5 (Immunotech), or CD38-PE (BD Pharmingen) and CD10-PC5 (BD Pharmingen), or 
CD23-PE (BD Pharmingen) and CD69-PC5 (BD Pharmingen).  For three color analysis, each set 
of cells was stained with CD19- PC7 (Beckman Coulter) and pan goat F(ab’)2 anti-human Ig’s-
FITC (Biosource International), plus CD5-PC5 (Immunotech) or CD40-PC5 (BD Pharmingen).  
For the nuclear proliferation marker Ki67, cells were first fixed with 1% paraformaldyhyde, 
washed and blocked in FACS buffer plus saponin, and then stained with Ki-67-PE (BD 
Pharmingen).  All antibody incubations were for 30 minutes at 4 degrees Celsius.  Isotype 
controls were IgG1-PE (BD Pharmingen), IgG2a-PC5 (Beckman Coulter), IgG1-PE 
(Pharmingen), and preimmune goat F(ab’)2 IgG control-FITC (Biosource International).  For 
each set of phenotypic markers, cells from 10 high load patients were analyzed on a Beckman-
Coulter XL flow cytometer and analysis was done with Cytomation Summit v3.1. 
Magnetic bead separations:  Peripheral blood mononuclear cells were presorted before 
separation in the MoFlo to help purify the cell populations.  Monocytes/macrophages and 
myeloid cells were positively sorted from the PBMC’s with Dynabeads M-450 CD14 and 
Dynabeads CD15 (Dynal Biotech Oslo, Norway).  Histopaque prepared PBMC’s from patient 
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 blood samples were mixed with Dynabeads at a concentration of 10^7 beads/ml and incubated at 
4 degrees Celsius for 30 minutes, with gentle rotation.  The positively selected cells were 
isolated with a Dynal MPC and discarded, while the negative fraction was saved for staining and 
further sorting.   
Cell staining for cell sorting:      PBMCs from high load patients that had been depleted of 
CD14+ and CD15+ cells were stained for two or three color sorts by incubating the cells with 
CD19-PE (Immunotech) and sIg-FITC (Biosource International), and in some cases, CD20-PC5 
(Immunotech) or HLA Class I-APC (BD Pharmingen).  The cells were incubated with the 
antibodies for 30 minutes at 4 degrees Celsius, then washed and resuspended in PBS.   
Cell Sorting:   The stained PBMC’s, devoid of CD14+ and CD15+ cells, were gated on the 
basis of CD19 positivity and side scatter, then sorted in a BD FACS Aria or Cytomation MoFlo 
(Modular Flow High Performance Cell Sorter) based on Ig positivity.  Cells that were at least 
one log less than the median of the Ig positive cloud were considered Ig negative.  Both CD19+ 
and CD19- fractions were collected directly into PCR lysis buffer (see below for composition), 
and a small amount of unsorted cells were also saved for QC-PCR.  For some patients, Ig-null 
cells were further sorted on the basis of CD20 or HLA Class I.  In such cases, the Ig-null CD20 
positive and negative fractions, or HLA Class I positive or negative fractions, were collected, as 
well as unsorted cells.   
Quantitative-Competitive PCR:  Peripheral blood mononuclear cells were prepared from 
whole blood patient samples by centrifugation onto a Histopaque (Sigma-Aldrich, St. Louis, MI) 
cushion. The cells were washed in phosphate buffered saline (PBS) and counted. Cell pellets 
were stored at –20 degrees C until ready for PCR. To make lymphocyte lysates 20µl of PCR 
lysis buffer (50 mM KCL, 10 mM Tris [pH 7.6], 2.5 mM MgCl2, 1% Tween 20, and 100µg of 
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 proteinase K per ml) was added for every 105 lymphocytes. The lysates were incubated at 55ΕC 
for 1 hr, boiled for 15 min to inactivate the proteinase K and chilled on ice. Primers for the PCR 
target sequence in the EBV genome were designed with OLIGO software (National Biosciences 
Inc., Plymouth, MN ). TP1Q5' ( AGGAACGTGAATCTAATGAAGA) and TP1Q3' ( 
GAGTCATCCCGTGGAGAGTA) amplify a 177-bp EBV sequence (exon 1) in the lmp2a gene. 
A competitor target was made by deleting 42-bp from a 177-bp EBV amplicon derive from the 
viral lmp2a exon 1 sequence. For each sample, five tubes containing 8, 40, 200, 1000 or 5000 
copies of the viral LMP2a competitor sequence along with lymphocyte lysates equivalent to 105 
cells were subjected to 30 cycles of amplification (94ΕC for 1 min, 54ΕC for 1 min and 72 ΕC 
for 1 min). Each PCR reaction (50µl) contained 20 pmol of 5' and 3' primers, 50mM  KCL, 2.5 
mM MgCl2, 10 mM Tris [pH 9.0], 0.1 % Triton X-100, and 0.25 mM deoxynucleotides (Pfizer, 
New York, New York). One unit of Amplitaq Gold DNA polymerase (Perkin Elmer, Wellesly, 
MA) was used in each reaction. The PCR products were analyzed on 2% agarose gels containing 
0.5X Tris-borate-EDTA electrophoresis buffer and 0.5µg of ethidium bromide per ml. 
 The QC-PCR assay for EBV is used to quantitate viral loads in the range of 8 to 5000 
copies of viral DNA in 105 lymphocytes. Normal latent infection (0.01 - 0.1 copies/105 
lymphocytes) is not detected by this protocol and detectable levels of viral DNA reflect a viral 
genome burden at least 2 to 3 orders of magnitude above normal latency. 
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 3.2.5. Results 
 
3.2.5.1. Frequency of Ig-Null Cells in High Load, Low Load, and No Load Patients 
 
To determine the frequency of Ig-null cells in transplant recipients and to determine if the 
frequency of Ig-null cells increases with viral load, we probed peripheral blood mononuclear 
cells from patients at Children’s Hospital of Pittsburgh with pan sIg-FITC and CD19-PE and 
analyzed them by flow cytometry.  Ten high load patients, 10 low load patients (as defined 
previously), and 11 transplanted patients with no detectable viral load (ND) were selected for the 
study.  CD19+ cells were gated based on the log of their side scatter and CD19 expression 
(Figure 9, top panel).  The gated cells were then examined for the expression of surface 
immunoglobulin.  A CD19+ cell was defined as Ig-null when its surface expression of Ig was at 
least one log below the median of the surface Ig expression of the Ig+ cloud.  (Figure 9, middle 
panel).  The presence of the Ig-null cells within the CD19+ gated population was then confirmed 
(Figure 9, bottom panel).   
 Ig-null cells were present in every patient examined.  The 10 high load patients examined 
had an average of 2.52%, with a broad range of 0.22-9.72% of CD19+ cells (Figure 10, top).  
Two patients in particular had a much higher frequency of Ig-null cells. Data from high load 
patient #9 is shown in Figure 9.  The frequency of Ig-null cells for this patient was 8.86% of the 
peripheral blood B cells.  High load patient #10 had the highest frequency of Ig-null cells at 
9.72%.  The 10 low load patients had lower frequency of Ig-null cells, with 0.95% of the CD19+ 
cells being Ig-null (Figure 10, middle).  This patient group also had a broad range, varying from 
0.12-4.25% of B cells.  The frequency of Ig-null cells was very low in the ND patient population, 
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 but still detectable.  This group averaged only 0.20% of CD19+ cells as Ig-null, with a range of 
0.01-0.92% (Figure 10, bottom). 
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Figure 9. Procedure for the detection of Ig-null cells (high load patient #9).   
The top panel shows the determination of the CD19+ cloud for gating purposes.  B cells are 
defined based on both the surface expression of CD19 and the log of the side scatter.  The middle 
panel shows Ig expression vs. CD19, as gated on the CD19 R1 region.  An Ig-null cell (box R2) 
is defined as being one log less than the median of the surface Ig positive cloud.  The bottom 
panel shows the cells highlighted from box R2 as they are dispersed in the CD19+ cloud.   
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Figure 10. Percent of Ig-null cells in the peripheral blood of high load (top), low load (middle), 
and ND (bottom) individuals. 
The percent of Ig-null cells of B cells from the peripheral blood was determined by staining 
PBMCs with CD19-PE and sIg-FITC and gating on the CD19+ cloud. 
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 3.2.5.2. Distribution of Viral Load in High Load Patients 
 
To determine what proportion of the increased viral load seen in high load patients is carried in 
the population of Ig-null cells, we sorted peripheral blood mononuclear cells based on the 
surface expression of CD19 and pan sIg.  PBMCs from high load patients were presorted for 
initial purification with CD14 and CD15 magnetic beads to remove contaminating monocytes 
and granulocytes.  At different times either a MoFLo (Modular Flow High Performance Cell 
Sorter) or a BD FACS Aria were used to sort the stained cells.  CD19+, sIg- and CD19+, sIg+ 
cells were collected from three patients; quantitative competitive PCR was performed on each 
sorted cell sample to determine the number of viral genomes in each sorted fraction.  QC-PCR 
was also conducted on a population of unsorted PBMC’s from each patient for a total viral load 
estimate.  QC-PCR results and the number of cells in each isolated cell population are shown for 
one representative patient. (Figure 11)  For the unsorted fraction, the number of CD19+, Ig +/- 
cells was calculated based on the known percentage of lymphocytes, CD19+ cells, and Ig-null 
cells. This number was then adjusted to reflect the number of cells per 20 ul reaction.  For the 
patient shown, a viral load of 400 was observed in the Ig-null sorted fraction (336 cells per PCR 
reaction).  In the CD19+, Ig+ sorted fraction a viral load of 200 was measured, (3682 cells per 
PCR reaction).  In the unsorted fraction, a viral load of 600 was observed in a fraction calculated 
to contain 321 Ig-null cells and 4760 CD19+, Ig+ cells.  By comparing the number of Ig-null 
cells in both the sorted and unsorted fraction, two-thirds of the viral load is in Ig-null cells.  
While the distribution of viral load varied from patient to patient, in all patients examined in this 
manner, it was clear that the Ig-null population of cells held a substantial portion of the viral 
load.  These results are shown in Table 4.   
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Figure 11. Distribution of viral load in one representative high load patient.   
The boxed gels represent QC-PCR reactions from each fraction of cells (left to right-unsorted, 
Ig-null, and Ig+).  For each gel, the 5 lanes represent (left to right) 5000,1000, 200, 40, and 8 
copies of the competitor. 
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Table 4. Viral loads detected by QC-PCR in Ig positive and Ig-null cells, as well as in the 
unsorted fraction.   
 
 
sIg 
 
Patient 1 
 
Patient 2 
 
Patient 3 
Fraction 
Unsorted 
(Ig+/Ig-
null) 
Ig-
null 
Ig+ Unsorted 
(Ig+/Ig-
null) 
Ig-
null 
Ig+ Unsorted 
(Ig+/Ig-
null) 
Ig-
null 
Ig+ 
Cells/ 
reaction 
 
17,589 
 
(4760/321) 
 
336 
 
3682 4x105 
(104/1760) 
 
416 
 
4000 
 
95,000 
 
(4896/104) 
 
442 
 
9030 
Viral 
load 
 
600 
 
400 
 
200 
 
5000+ 
 
400 
 
2000 
 
2000 
 
4000 
 
10,000 
 
 
sIg 
 
Patient 4 
 
Patient 5 
Fraction 
Unsorted 
(Ig+/Ig-
null) 
Ig-
null 
Ig+ Unsorted 
(Ig+/Ig-
null) 
Ig-
null 
Ig+ 
Cells/ 
reaction 
 
13,000 
 
(151/7) 
 
657 
 
7030 
 
6000 
 
(42/1) 
 
543 
 
8190 
Viral 
load 
 
80 
 
200 
 
100 
 
N/A 
 
200 
 
200 
 
 
N/A = not-amplifiable 
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 3.2.5.3. Phenotype of Ig-Null Cells in High Load Patients 
 
Since Ig-null cells by definition have an aberrant B cell phenotype and also appear to 
disproportionately carry the viral load in high load patients, we analyzed Ig-null cells for the 
expression of other B cell phenotypic markers with four color flow cytometry.  CD19 and sIg 
were used to define the Ig-null population in each sample in conjunction with other surface 
markers.  Because of limited cell number from each patient, different groups of high load 
patients (groups a-f) were examined for various surface markers.  There were no significant 
differences between the high load patient group examined for each cell surface marker.  Initially 
the Ig-null cells in the peripheral blood of 10 high load patients (group a) were examined for 
HLA Class I and Class II (Figure 12a).  More than one third (36.9%) of the Ig-null cells in these 
patients were HLA Class I negative, with two patients in particular (patients 4 & 10) having a 
high percentage of the Ig-null cells HLA Class I negative, with 85.5 and 85.6 % respectively.  
Approximately one third (36.4%) of Ig-null cells were HLA Class II negative.  Interestingly, the 
two patients with high numbers of Ig-null, HLA Class Ineg cells did not have a high number of Ig-
null, Class II negative cells, although two other high load carriers (patients 6 & 9) did show high 
levels of HLA Class IIneg, Ig-null cells, with percentages of Class II neg cells at 76.5 and 95.3% of 
Ig-null cells, respectively. 
 B cell phenotypic markers were also examined on Ig-null cells from 12 high load patients 
(group b) (Figure 12b).  B1 and B2 type cells can nominally be classified by the surface 
expression of CD5. Ig-null cells were predominantly CD5 negative (88.2%) suggesting a 
possible B2 type origin.  CD20 is a B lineage marker found on all B cells and is particularly 
important because it is the basis of destruction of B cells with anti-CD20 monoclonal antibodies 
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 in clinical trials treating PTLDs that fail to respond to conventional therapies. In the high load 
carrier population, half (49.2%) of the CD19+, sIg- cells were also CD20neg.  One patient (Patient 
#3) for whom 1.3% of all B cells were Ig-null cells, 79.1% of the Ig-null cells were CD20neg.  
Another patient (#10), with 5.5% Ig-null cells in the B cell population showed a similar pattern 
with 78.6% of Ig-null cells also being CD20neg. CD20 was broadly expressed on B cells in these 
patients, as 95.45% of all CD19+ cells were also CD20+ (data not shown).  Memory B cells can 
be detected by the presence of somatically mutated Ig genes and expression of CD27. In 11 high 
load carriers (group c), 87.5% of the Ig-null cells were CD27neg.  Overall, 86.6% of the CD19+ 
cells in the circulation were CD27neg (data not shown).  Peripheral blood B cells have been 
shown to express CD40. In this group of 10 high load patients (group f), 96.2% of CD19+ cells 
expressed this marker.  However, nearly 40% (39.1%) of the Ig-null cells did not have CD40 on 
their surface. 
 Ig-null cells from high load patients were examined for the presence of surface activation 
(CD23 and CD69) (group d) and germinal center markers (CD10 and CD38) (group e) (Figure 
12c).  Flow analysis suggested the Ig-null cells were non-activated, with a very small percentage 
of CD23 and CD69 expressing cells (1.45% and 2.66% respectively).  In the CD19+ population, 
percentages of 1.6% (CD23) and 1.01 % (CD69) were observed.  Similarly, Ig-null cells did not 
carry the germinal center markers CD10 and CD38 on their surface (2.22% positive and 9.42% 
positive, respectively).  The circulating CD19+ population as a whole had similar small 
percentages of these markers, with 3.4 and 2.8% expressing CD10 and CD38.  Ig-null cells from 
10 high load patients (group f) were permeabilized and stained for the proliferating cell marker 
Ki67 (Figure 12c).  2.72% of the Ig-null cells were positive.  Overall, in the gated CD19+ 
population, only 1.2% were positive for Ki67. 
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Figure 12a. Percent of Ig-null cells displaying B cell phenotypic markers.  
PBMCs from 10 high load patients were stained with various surface antibodies (see materials 
and methods for complete list) and analyzed by flow cytometry.  A shows the percent of cells 
expressing HLA Class I and II.  For each graph, percents are expressed as percent of B cells, and 
the patients are ordered 1-10 according to the increasing amount of Ig-null cells in their 
peripheral blood. 
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Figure 12b. Percent of Ig-null cells displaying B cell phenotypic markers.  
PBMCs from 10 high load patients were stained with various surface antibodies (see materials 
and methods for complete list) and analyzed by flow cytometry.  B shows the percent of cells 
expressing B cell markers CD5, CD20, CD40 and CD27.  For each graph, percents are expressed 
as percent of B cells, and the patients are ordered 1-10 according to the increasing amount of Ig-
null cells in their peripheral blood. 
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Figure 12c. Percent of Ig-null cells displaying B cell phenotypic markers.  
PBMCs from 10 high load patients were stained with various surface antibodies (see materials 
and methods for complete list) and analyzed by flow cytometry.  C shows the percent of cells 
expressing activation and germinal center markers, as well as a proliferation marker.  For each 
graph, percents are expressed as percent of B cells, and the patients are ordered 1-10 according to 
the increasing amount of Ig-null cells in their peripheral blood. 
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 3.2.5.4. Compartmentalization of Viral Load in High Load Patients 
 
Approximately one half of the Ig-null cells in high load patients were CD20 negative and thus 
would presumably be resistant to rituximab therapy.  Another third of Ig-null cells are HLA 
Class I negative and thus unable to present targets for antigen specific cytotoxic T cells.  An 
increased concentration of viral load in these cell populations would have important implications 
for immunotherapeutic approaches to lymphoproliferative disease.   
We examined the elevated viral load in these patients to determine whether it is carried in 
the Ig-null, CD20neg and/or HLA Class Ineg compartment.  In the two patients whose Ig-null cells 
were sorted into HLA Class I positive and negative fractions, different distributions of viral load 
were observed.  Patient one (Table 5) had a viral load of 400 in the unsorted fraction. From the 
total number of cells and the percentages of CD19+, Ig-null, and HLA Class Ineg cells, it can be 
calculated that the PCR reaction on the unsorted fraction contained approximately 35 Ig-null 
cells of which only 1 would be a double negative cell.   In the Ig null fraction, the HLA Class Ipos 
reaction had 205.7 cells, and a viral load of 200 genome copies.  The HLA Class Ineg reaction had 
just 5 cells, and a viral load of 40 genome copies.  By comparing the viral load in the sorted 
populations to the viral load in the unsorted fraction, we determined that the viral load was not 
enriched in the Ig-null, HLA Class Ineg fraction.  On the other hand, the same analysis in the 
other high load patient examined did have an enriched viral load in the Ig-null, HLA Class Ineg 
compartment.  The unsorted fraction had a viral load of 400, with a calculated number of Ig-null, 
Class I positive and negative cells of 106 and 2 cells, respectively.  The sorted Ig-null, HLA 
Class Ipos fraction had a viral load of 80 genome copies in 171 cells.  The sorted double negative 
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 fraction had a load of 400 genome copies indicating that in this patient there was a significant 
enrichment of the viral load in the Ig-null, HLA Class Ineg compartment (Table 5).   
 PBMCs from three patients were sorted for their Ig-null, CD20neg populations (Table 6).  
While virus was detected in the CD20neg population in 2 patients, the levels were not 
significantly enriched.  For patient three, the 8.66 sorted Ig-null, CD20neg cells per PCR reaction 
did carry an elevated viral load of 100 genome copies, while the 81.2 Ig-null, CD20pos fraction 
had a viral load of only 80. In this patient, the Ig-null, CD20neg fraction disproportionately 
carried more of the viral load.  Patient 2 had no detectable viral load in the Ig-null, CD20neg 
compartment, while Patient 1 carried a proportional viral load.  These results are summarized in 
Table 6.   
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Table 5. Viral loads detected by QC-PCR in HLA Class I positive and negative Ig-null 
cells, as well as in the unsorted fraction. 
 
 
 
 
Table 6. Viral loads detected by QC-PCR in CD20 positive and negative Ig-null cells, as 
well as in the unsorted fraction.  
 
 
 
 
HLA Class I 
 
Patient one 
 
Patient two 
 
Fraction 
 
Unsorted 
(Ig-null) 
 
Ig-Positive 
 
Ig-negative 
 
Unsorted 
(Ig-null) 
 
Ig-positive 
 
Ig-negative 
 
Cell#/rxn 
 
34.8 
 
205.7 
 
5.1 
 
108 
 
171 
 
2.8 
 
Viral load 
 
400 
 
200 
 
40 
 
400 
 
80 
 
400 
CD20 
 
Patient one 
 
Patient two 
 
Patient three 
 
Fraction 
 
Unsorted 
(Ig-null) 
 
Ig-Positive 
 
Ig-negative 
 
Unsorted 
(Ig-null) 
 
Ig-positive 
(Ig-null) 
 
Ig-negative 
 
Unsorted 
(Ig-null) 
 
Ig-positive 
 
Ig-negative 
 
Cell#/ 
Rxn 
 
35.5 
 
299 
 
130 
 
4.1 
 
126 
 
1.73 
 
25.8 
 
81.2 
 
8.66 
 
Viral 
load 
 
800 
 
400 
 
40 
 
80 
 
8 
 
0 
 
200 
 
80 
 
100 
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 3.2.6. Discussion 
 
Previously, we reported the presence of CD19+, Ig null cells in the peripheral blood of pediatric 
solid organ transplant patients with a high load of Epstein-Barr virus (29).  By fluorescent in situ 
hybridization, we demonstrated that a large portion of the viral load was carried in high copy 
numbers with in Ig null cells, while cells with a low copy number of EBV genomes were 
predominately IgM+, in both high and low load carriers (29).  In the current study, we present 
data that suggests that Ig null cells are present in all transplant recipients and that their level is 
highest in high load patients.  The high load group had, on average, two and a half times the 
percentage of Ig-null cells in the peripheral blood as compared to the low load group, and more 
than ten times the percentage of Ig-null cells as compared to the ND group.   
In an effort to determine the phenotype of Ig-null cells, we examined a number of 
immunologically relevant surface markers on the CD19+, Ig-null population.  Normal latently 
infected B cells are CD27+, and have a resting B2 cell phenotype (1, 2, 19, 20, 26).  While we 
found that Ig-null cells were non-proliferating, and lacked germinal center and activation 
markers, we also determined that nearly all these cells were CD27neg and approximately half of 
the cells did not have the ubiquitous CD20 B cell marker on their cell surface.  Moreover, 
approximately one third of Ig-null cells also lacked HLA Class I and II markers.  Ig-null cells 
were CD5neg consistent with a B2 cell type profile. Thus, while the Ig-null cells had variable 
surface expression of some markers, as a whole they did not match the recognized phenotype of 
normal latently infected cells (1, 2, 19, 20, 26).  In addition, it is unclear how long-lived Ig-null 
cells are in the circulation.  Many high load carriers over a period of six to 12 months tend 
towards reduced viral loads and eventually become, by definition, low load carriers. These 
converters to load status do not carry an elevated number of Ig-null cells or high genome copy 
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 cells suggesting a direct relationship between the drop in viral load and the loss of the null cells 
from the circulation as time progresses (data not shown).  
By sorting Ig-null cells from the peripheral blood of high load patients and performing 
quantitative PCR on the sorted populations, we determined that a large fraction of the elevated 
viral load was being carried in the Ig-null subpopulation.  Importantly, it can be deduced that not 
all Ig-null cells are high copy EBV+ cells.  This is demonstrated by both the detectable 
population of Ig-null cells in the ND patients, as well as the viral loads detected in the sorted 
CD19+, Ig-null fractions from the high load patients.  While these viral loads were certainly 
elevated and concentrated in this fraction, the load would still be expected to be much higher if 
all the cells were carrying 10 or more viral genomes.  This confirms the previous study, in which 
a percentage of Ig-null, EBV negative, CD19+ cells were observed in both high and low load 
patients (29).  The origin of Ig-null cells seems most likely to be from germinal center reactions 
in which unsuccessful Ig affinity maturation and/or isotype switching has occurred. This explains 
the lack of expression of surface immunoglobulin. In the context of an EBV infection, EBV 
could provide the necessary survival signals to prevent apoptosis. However, Ig-null, EBV 
negative cells were detected in this study and this suggests that the process is likely not entirely 
EBV dependent. The immunosuppression of transplant recipients is likely to be a major factor in 
allowing Ig-null cells to escape apoptosis and persist.  EBV may be a key player in the 
modification of a microenvironment within the germinal center that allows for the enhancement 
of protection of both uninfected as well as infected Ig-null cells.  Such an environment might 
also contribute to the loss of B-cell differentiation and maturation markers from a large fraction 
of the Ig-null B cells.  Kuppers et al (2003) observed a similar loss of B-cell markers on the 
Reed-Sternberg cells of classical Hodgkin’s Disease (3).  While their group examined RNA 
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 expression, and in the present study we analyzed surface protein expression, a similar 
phenomenon of B-cell identity loss in the Ig-null cells of transplant patients appears to be 
occurring.  A comprehensive gene expression profiling of the Ig-null cells would further clarify 
their phenotypic status.   
Throughout this study we have used CD19 to define the B cell population. We have not 
determined the prevalence of CD19 negative null cells in our patient populations.  CD20 is also 
often used to gate B cells from mixed populations.  When PBMCs from 10 high load carriers 
were gated on CD20, on average approximately 0.78% of the gated cells were Ig-null and only 
0.05% of the CD20+ cells were both CD19neg and Ig-null (data not shown).  These observations 
show that there were very few CD20+, CD19neg, Ig-null cells in the circulation.  Thus, very few 
Ig-null cells were missed by gating on the CD19+ population.  Since nearly half of the CD19+, 
Ig-null cells are CD20neg, CD19 is clearly a better B cell marker for defining the population and 
examining Ig-null B cells.  Because Ig-null cells carry a significant viral load and half of Ig-null 
cells are CD20-, the possibility exists that some PTLDs cannot be effectively treated with 
rituximab (anti-CD20 antibody). Previous studies examining the efficacy of rituximab have 
shown varied responses, with overall response rates around 60-70% (7).  The largest study to 
date involved 32 patients, with either solid organ or bone marrow transplantation.  The overall 
response included 20 complete responses and 2 partial responses, for an overall rate of 69% (18).  
Various factors, including CD20 positivity and performance status, appear to be the major 
predictors of response to rituximab (7).  Our current study shows that elevated viral loads are 
often carried in aberrant B cells, which would be predicted to be non-responsive to rituximab-
based therapies.   
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 Taken together, the results suggest that the persistent EBV infection of pediatric solid organ 
transplant recipients is complex and dynamic.  Because Ig-null cells have been shown to be 
involved in such EBV-associated disease states, as angioimmunoblastic lymphadenopathy with 
dysproteinemia (AILD), EBV positive Hodgkin’s Disease, and PTLD (3, 4, 12, 14, 33), their 
presence in the peripheral blood of asymptomatic children with high EBV loads warrants 
monitoring.  If such cells would give rise to a PTLD or lymphoma, current therapeutic 
approaches may be ineffective. 
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 4. DISCUSSION 
While Epstein-Barr virus is normally carried as a harmless passenger in infected individuals, it 
has also been linked to several severe malignancies.  The focus of this project was a population 
of individuals who are at an elevated risk for EBV-associated posttransplant lymphoproliferative 
disease (PTLD).  Pediatric transplant patients are an elevated risk group because they are 
seronegative at the time of transplant.  Advances in understanding the pathogenesis of EBV 
infection and the development of PTLD in this patient population are needed.   
 
4.1. THE PRESENCE OF IG-NULL CELLS 
 
The patients in this study were transplant recipients who did not have PTLD.  Many of these 
patients did carry a characteristic elevated viral load in their peripheral blood.  They were 
classified as either high load carriers, low load carriers, or non-detectable (ND) patients, 
according to previously published criteria (16).  Briefly, high load carriers have a viral burden in 
their peripheral blood of >200 viral genomes per 105 lymphocytes.  Low load carriers have a 
viral burden between 8 and 200 viral genome copies in 105 lymphocytes, and ND patients have 
<8 viral genome copies in 105 lymphocytes.  In each case, this viral load must be carried stably 
for at least two months to meet the classifications.  Previous work in this laboratory involved a 
characterization of EBV infected B cells in the peripheral blood from this patient population.  
The two main findings were 1) the EBV load is carried exclusively in the IgD negative B cell 
compartment (non-naïve), and 2) high and low load carriers harbor their elevated viral loads 
differently (18, 19).  The difference is that high load carriers have a distinct population of 
infected cells that have high copy numbers of viral genomes (10+).  They also have a population 
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 of low copy number cells with just 1-2 viral genomes per nucleus.  Low load carriers carry the 
their viral load predominately in low copy number cells.  High copy cells were only detected in 
low load carriers in very rare instances (19).  In normal individuals, the EBV genomes are 
carried in the peripheral blood as low copy cells, just as it is in the low load carriers. 
One issue that is important to understanding the pathogenesis of disease in 
immunocompromised patients is how high and low copy cells arise during the course of virus 
infection.  The presence of viral genomes in low copy cells can be readily accounted for by the 
Random Assortment Model for virus replication (Figure 13).  This model requires three 
assumptions about virus infection: 1) only one virus particle infects each cell, 2), the viral 
episomes only replicate once per cell cycle and 3) there is EBNA1 mediated random assortment 
of the viral genomes to the daughter cells at the M phase of the cell cycle (19).  The high copy 
cells observed in the high load patients cannot be accounted for by a mechanism involving 
random assortment alone (19).  This suggests that high copy cells probably have a different 
pathway of infection than low copy cells.  The present work was initiated to analyze the 
characteristics of high copy cells that could yield an explanation of their origin and fate in the 
context of EBV infection, immunosuppression and lymphoproliferative disease.  While there are 
more questions to be answered (see Future Directions, below), some important conclusions were 
uncovered concerning the origin of high copy cells within the overall scheme for ontogeny of B 
cells.   
 It was already determined that the EBV load was carried exclusively in an IgD- 
population (18).  Since IgD is a marker for naïve B cells, the result suggested that B cells might 
be further along in the B cell maturation process.  Determining if the infected cells had gone 
through a germinal center reaction, and thus had possibly undergone isotype switching would be 
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 useful.  An examination of B cell receptor usage in 8 high load patients examined by a 
combination FISH/IF procedure, 68% of the infected cells with high copy numbers had no 
detectable surface expression of immunoglobulin (Ig-null cells).  Ig-null cells were observed in 
every high load patient, and in some patients, up to 85% of their high copy infected cells were 
Ig-null.  Low copy cells in both high and low load patients were predominately IgM positive.  In 
both the high and low load carrier groups, three patients had a prior history of PTLD.  The 
PTLDs in all 6 patients were fully resolved at the time of the current study.  These 6 patients did 
not differ significantly from another of the other patients in the isotypes of their infected cells.  
The 3 low load patients that had a prior history of PTLD did have the highest percentages of Ig-
null high copy cells, but these values were not dramatically different.  Further, high copy cells 
were still very rare in these patients.  High percentages of Ig-null cells were detected in low load 
patients that did not have a prior history of PTLD.   
To appreciate the significance of Ig-null cells, an understanding of fundamental B-cell 
ontogeny is necessary. 
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Figure 13. The Random Assortment Model (19). 
 
107 
 4.2. B-CELL ONTOGENY 
 
The earliest stages of B cell development occur in the bone marrow and are dependent on non-
lymphoid stromal cells.  B cells derive from pluripotent hemopoietic stem cells, and the earliest 
form of B-lineage cell is called a pro-B cell (7).  In these B cells, the rearrangement of heavy 
chain immunoglobulin gene segments takes place.  Pro-B cells differentiate into pre-B cells, 
which express an intact heavy chain on the cell surface as a preliminary step in the assembly of a 
functioning B cell receptor (BCR).  Once one of the light chain genes is rearranged and a light 
chain is synthesized, a complete IgM molecule can be expressed on the surface.  The cell is now 
viewed as an immature B cell (7).  After passing self-tolerance tests, the immature B cell is 
released from the bone marrow to circulate in the peripheral blood and further differentiate into 
naïve B cells, expressing IgD in addition to IgM.  As they recirculate through the secondary 
lymphoid organs, they await contact with antigen to develop into mature B cells.  Throughout 
this initial developmental process, a large number of B cells have died because of nonproductive 
rearrangements owing to imprecise joining of their immunoglobulin gene segments.  The heavy 
chain locus in particular leads to a high percentage of cell loss (11).  
 When antigen-naïve, self-tolerant B cells leave the bone marrow, they circulate to the 
secondary lymphoid organs and enter through high endothelial venules (17).  If they encounter 
their cognate antigen, usually in the outer T-cell zone of lymphoid organs, they become 
activated, with the help of their interaction with CD4+ T helper cells and follicular dendritic 
cells.  These activated B cells then migrate to B-cell follicles in the lymphoid organs, and start to 
proliferate and differentiate into centroblasts.  These B cell follicles become germinal centers 
(13), where intense proliferation and somatic hypermutation of their rearranged V-region genes 
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 takes place (10).  Centroblasts differentiate into resting centrocytes, which must be selected for 
high affinity of their recently rearranged BCR to cognate antigen.  At this point in B cell 
development, two survival signals must be received by the centrocyte to rescue it from a default 
pathway leading to apoptosis.  The first signal is delivered through the somatically mutated 
immunoglobulin molecule as it demonstrates high affinity binding to cognate antigen (12).  The 
second signal is delivered by a cognate interaction between CD40 on the B cell and a T-cell 
expressing CD40L (the CD40 counter-receptor) (12).  If such signals are received, the B cell can 
recycle to further mutate and/or undergo the isotype switching process to become a mature 
memory B cell.  Alternatively, without the two crucial survival signals, they are programmed to 
undergo apoptosis.  Memory B cells express IgA, IgG, or IgM, and have lost the expression of 
IgD.  After selection, a B cell can also terminally differentiate into a plasma cell.  Plasma cells 
do not express CD19, nor do they express surface immunoglobulin.  Both memory and plasma 
cells exit the germinal center and enter the peripheral circulation.  See Figure 14 for a pictorial 
view of B cell ontogeny, as described above.  
 A subset of B cells in humans develops in a different manner and these cells are termed 
B1 cells.  These cells develop in the fetus and are self-renewing.  They have distinctive receptors 
and functions from conventional (B2) cells.  These cells were first identified by their surface 
expression of CD5, and are IgM positive and IgD negative (7).  While they are sparsely found in 
the lymphoid organs, they are the main B-cell population in the peritoneal and pleural cavities.  
B1 cells somatically hypermutate very little, if any, and tend to bind to many different ligands 
with low affinity, suggesting that they mediate a more primitive early immune response (7).  B1 
cells continually divide in peripheral sites and have been linked to the chronic lymphocytic 
leukemia.  Some speculation exists that PTLDs may have a linkage to B1 cells.   
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  As the CD19+ B cells in this study do not express surface immunoglobulin (functional 
BCR), theoretically they should have apoptosed during the germinal center reaction, as the first 
survival signal was not received.  Without a functional BCR, B cells are pre-programmed to 
undergo apoptosis.  The aberrant Ig-null cells detected in this study must be receiving an 
alternative signal to allow them to survive in the periphery without surface expression of 
immunoglobulin.  The majority of low copy cells in this study express IgM, suggesting that they 
did not undergo the isotype switching process in the germinal center and have not necessarily 
arisen from a germinal center reaction.  Because the high copy Ig-null cells have an aberrant 
immunoglobulin phenotype and are missing one of two crucial signals necessary for the survival 
of the B cell, we investigated further and determined the frequency of such cells in the peripheral 
blood of pediatric solid organ transplant recipients by flow cytometry. 
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Figure 14. Normal B2 cell ontogeny. 
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 4.3. IG-NULL CELLS IN PATIENTS AND EBV-ASSOCIATED MALIGNANCIES 
 
Prior to determining the frequency of Ig-null cells in the peripheral blood of pediatric solid organ 
transplant recipients, we suspected that high load patients would have the highest frequency of 
Ig-null cells.  These patients had the highest frequency of high copy cells.  The analysis revealed 
that high load patients had the highest frequency of Ig-null cells, followed by low load patients 
and finally transplanted patients with no detectable viral load.  One striking feature of the data is 
the broad range of Ig-null cell frequencies observed in each patient group.  It would be 
interesting to follow the patients with the highest number of Ig-null cells in their circulation over 
time to see if they develop an EBV-associated complication.  Additionally, it can be deduced that 
Ig-null cells are not extremely long-lived, at least in some patients.  Low load patients that were 
formerly high load patients did not demonstrate the presence of high copy EBV-infected Ig-null 
cells at levels associated with high load patients.   
 Ideally, we need to examine the frequency of Ig-null cells in the peripheral blood of 
normal immunocompetent children who have not received an organ transplant.  We would then 
be able to determine the extent to which such cells are a normal constituent of the B cell 
repertoire or if they are an aberration connected to organ transplantation and thus the degree to 
which they are an aberration connected to organ transplantation the immune suppression 
associated with it.  When developing the flow cytometry protocol for this specific aim, we 
examined the frequency of Ig-null cells in the peripheral blood of a normal immunocompetent 
adult.  Although the frequency was very small, Ig-null CD19+ cells were present.  It would be 
interesting to determine if the presence of Ig-null cells is consistent across all age groups, or if 
they increase or decrease with age.  In any case, it is clear that without surface expression of 
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 immunoglobulin, these CD19+ cells are circumventing the normal checkpoint controls over B 
cell ontogeny and must be receiving a survival signal or ignoring an apoptotic one.   
 This is the first examination of Ig-null cells in the peripheral blood.  In other EBV-
associated malignancies, B cells deficient in the expression of immunoglobulin have been 
detected within the tumor mass.  In Hodgkin’s lymphoma, tumors are characterized by Hodgkin-
Reed Sternberg Cells (HRS), even though they typically encompass less than 1% of the tumor.  
Such cells are atypical B cells that often have nonsense mutations, stop codons, or other 
deleterious mutations in their Ig locus, preventing the expression of immunoglobulin on the cell 
surface (9).  These cells are “crippled” germinal center cells and are receiving a survival signal to 
prevent their normally efficient elimination.  It has been proposed that the survival signal is 
provided by EBV, as HRS cells express the Latency II pattern (6).  In this case, LMP2A would 
replace the BCR signal, and LMP1 would replace CD40 stimulation.  Further, after examination 
of HRS cells by serial analysis of gene expression (SAGE), it was found that these cells 
demonstrated a loss of B-lineage specific genes and (in some cases), the protein product (20).  It 
is possible that the loss of B cell identity exhibited by these cells might also contribute to their 
survival in the absence of the normally required survival signals.  
 Additionally, such “crippled” (Ig-null) cells have been described in angioimmunoblastic 
lymphadenopathy with dysproteinemia (AILD).  AILD is a frequent T cell lymphoma in the 
Western world (3), in which large numbers of EBV-infected B cells sometimes infiltrate the 
tumor.  Upon examination of the immunoglobulin genes in these B cells micromanipulated from 
cases of AILD, it was shown that the EBV infected cells represented clones of an EBV infected 
memory or germinal center B cell.  Further, these cells showed marked continued hypermutation, 
in the absence of the typical germinal center environment.  Often times, these clones showed 
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 destructive mutations in their originally functional variable gene rearrangements, which resulted 
in both the survival and clonal expansion of Ig-null B cells.  In rare instances, the crippled B 
cells were even shown to be EBV negative.  Clearly, the microenvironment associated with 
AILD, interplayed with EBV infection, enables an aberrant B cell to survive and clonally expand 
(3).  
 A third scenario in which an EBV-associated malignancy shows the presence of Ig-null 
cells is PTLD.  Recent evidence (21) demonstrated that in a proportion of cases of PTLD, tumor 
development is associated with post-germinal center cells that have randomly mutated or sterile 
(crippled, Ig-null) heavy chain genotypes.  Such cells have failed the germinal center process that 
selects naïve B cells into memory, but still survive in the periphery and become involved in the 
pathogenesis of PTLD.  Because of the immunosuppression associated with organ 
transplantation, the ongoing somatic hypermutation sometimes observed in these cells is 
occurring in the absence of the normal physiological environment of germinal centers (CD4+ T 
cells and follicular dendritic cells) (4).  Further, a flow cytometric evaluation of PTLD tumors 
showed a distinct lack of surface immunoglobulin light chains in 36% of the cases studied (8).  
Overall the presence of Ig-null cells in EBV-associated PTLDs suggests that they may be 
involved in the pathogenesis of this disease.  
 Ig-null cells have not been described in disease states not associated with EBV.  This is 
the first study showing that they are present in disease-free individuals.  While the patients 
studied here have elevated viral loads in their peripheral blood, they showed no signs or 
symptoms of PTLD or any other EBV-associated malignancy.  With the presence of Ig-null cells 
with high copy numbers of EBV in their peripheral blood, they may have an elevated risk of 
developing an EBV-associated malignancy.  In a previous study by our lab, RNA transcripts for 
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 both LMP2a and LMP1 were detected in high load patients; transcripts for LMP2 only were 
detected in low load patients (16).  With the preponderance of high copy, Ig-null cells surviving 
in the peripheral blood of high load patients, it is proposed that LMP1 and LMP2A are providing 
the necessary signals for their survival.  In future experiments, this will be addressed. 
 
4.4. PHENOTYPE OF IG-NULL CELLS 
 
Because of the aberrant nature of Ig-null cells, we were interested in determining the status of 
other phenotypic characteristics that could describe their differentiation and activation states.  
The loss of B-cell identity associated with HRS cells in Hodgkin’s Disease, led us to suspect that 
the Ig-null cells might have similar aberrations.  We examined a variety of surface phenotypic 
markers typically associated with B cells in an effort to clarify this issue.  It has been shown that 
latently infected B cells in the peripheral blood of immunocompetent (non-transplanted and non-
diseased) individuals have the phenotype of resting memory B2 cells (1, 2, 15); we endeavored 
to determine if Ig-null cells in high load patients displayed a similar phenotype.  
 In addition to the lack of surface immunoglobulin, Ig-null cells had significant 
aberrations in their B cell marker phenotype.  The typical Ig-null cell in a high load patient was 
CD19+, sIg-, CD5-, CD10-, CD38-, CD27-, CD23-, CD69-, and Ki67-, with variable expression 
of HLA Class I and II molecules, CD20 and CD40.  Based on the expression of this set of 
markers, Ig-null cells appear to be inactivated (CD23 and CD69 negative), nonproliferative 
(Ki67-), B2 (CD5-), nongerminal center cells (CD10- and CD38-), and in addition did not 
display a marker for B cell memory (CD27-).  Further, one third of Ig-null cells were HLA Class 
I negative; and another one third were HLA Class II negative.  Without HLA molecules to 
115 
 display antigenic peptides on their surface for recognition by antigen specific cytotoxic T cells, 
these cells would not be eliminated by the immune system.  Approximately 40% of the Ig-null 
cells were also negative for surface expression of CD40 and would be unable to receive T-cell 
help through CD40-CD40L interactions.  These cells are missing both the survival signals 
(functional Ig molecule, CD40:CD40L interaction) required by B cells to avoid apoptosis.  
Finally, half of the Ig-null cells examined had no surface expression of CD20.  In a previously 
mentioned study of PTLD tumors examined by flow cytometry, one fourth of the tumors 
analyzed showed a complete lack of CD20 expression (8).  CD20- B cells could be unfortunate 
for therapeutic reasons.  PTLDs have been treated with rituximab, a monoclonal anti-CD20 
antibody to purge the patient of B cells and coincidentally of EBV infected cells.  CD20- B cells 
would not be eliminated by this treatment, and if the virus is residing in these cells, the chance 
for non-responsiveness to treatment and/or relapse is greater.  To date, the response rate to 
rituximab is around 60-70% (5, 14).  Our study suggests that if a PTLD is non-responsive to 
therapy, the patient should be examined for the presence of CD20- Ig-null cells in the peripheral 
blood, and treatment adjusted accordingly. 
 
4.5. COMPARTMENTALIZATION OF VIRAL LOAD  
 
To determine if a significant viral load is carried in Ig-null cells, they were purified from 
PBMC’s.  By sorting out the Ig-null cells (based on CD19 and pan-Ig expression), we were able 
to determine that a substantial portion of the elevated viral load in high load patients was carried 
in the Ig-null compartment.  In some patients, it seemed that the bulk of the viral load was 
carried in this compartment.  It should be noted that this compartment of B cells often makes up 
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 as little as 0.01% of PBMC’s.  To find a large portion of the virus concentrated in this tiny 
compartment is interesting.  
 Because of the low frequency of expression of CD20 and HLA Class I on the surface of 
high copy cells, we wanted to determine if the viral load was further compartmentalized into the 
Ig-null/CD20 negative and or Ig-null/HLA Class I negative compartment.  As these were 
extremely small populations in the peripheral blood, it was difficult to sort for these cells and 
obtain large numbers for study.  Nevertheless, we did recover sufficient cells to support some 
preliminary findings.  CD20 had a variable enrichment of viral load in the Ig-null/CD20 negative 
compartment.  HLA Class I negative, Ig-null cells also showed varying enrichment in two 
patients.  As cells that do not have expression of HLA Class I on their surface are normally 
efficiently eliminated by natural killer cells, it is unclear how the HLA Class I negative cells are 
surviving in the periphery.  Notably, in some patients, viral load was concentrated into less than 
0.01% of the peripheral blood mononuclear cells.  In patients showing no signs of clinical 
disease, EBV survives in an aberrant B cell.  Since these cells have many characteristics of 
malignant B cells, these patients might benefit from close monitoring of viral load in their 
peripheral blood in an effort to detect possible complications as early as possible. 
 
4.6. PROPOSED ORIGIN OF IG-NULL CELLS 
 
While firm conclusions cannot yet be made regarding the origin of Ig-null cells, a model can be 
proposed to explain the possible generation and persistence of Ig-null cells in immunosuppressed 
individuals (Figure 15).  In this model, EBV infects naïve or memory B cells in the oropharynx.  
Both types of cells migrate to germinal centers and undergo clonal expansion and somatic 
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 hypermutation.  The cells that will eventually become Ig-null cells undergo random somatic 
mutation, with nonproductive rearrangements.  Further, these potential Ig-null cells express the 
Latency II type profile (LMP1 and LMP2a).  Low copy cells may also express this profile or 
develop in a manner similar to normal uninfected B cells.  Because EBV is providing the two 
crucial survival signals necessary for the prevention of the apoptotic pathway, the infected cells 
can circumnavigate the light zone of the germinal center.  Normally in this area of the germinal 
center, somatically mutated B cells interact with follicular dendritic cells and T cells to receive 
the signals to prevent apoptosis.  Because LMP2a can provide the signal normally provided by 
an intact BCR and LMP1 can provide the signal normally provided by CD40:CD40L interaction, 
the infected cells do not need to receive these signals in the microenvironment of the light zone 
of the germinal center. Further, LMP1 and LMP2 are not highly immunogenic proteins; 
immunosuppressed patients have decreased CTL and thus the host is not as vigilant in 
eliminating virus-infected cells.  This would allow the virus infected cells to persist in the 
peripheral blood of pediatric solid organ transplant recipients.  Low copy cells emerge from the 
germinal center without isotype switching, but with the loss of IgD.  These cells persist in the 
peripheral blood as resting memory B2 cells, as in a normal immunocompetent host.  High copy 
Ig-null cells emerge from the germinal center, as well, but could continue to undergo somatic 
hypermutation and continue to express the latency II profile.  Downregulation of B cell identiy 
markers may also be occurring in the peripheral blood in a gradual process.  
 An alternate explanation for the generation of Ig-null cells could involve B1 cells.  These 
are the cells that follow the alternative pathway to B-cell development.  There are several 
observations that could be construed to support the idea that Ig-null cells arise from B1 cells.  
PTLDs most often arise in extranodal sites; B1 cells are very rare in lymph nodes, but are the 
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 predominant B cell population in the peritoneal cavity.  Further, PTLD’s are more common in 
pediatric transplants than in the adult transplanted population, and as B1 cells develop early in 
fetal development and then self-renew in the peripheral blood, they may be more common in 
children.  B1 cells also express high levels of IgM, and are not known to express IgD or CD23.  
It is well-known that the EBV viral load in infected individuals is carried in the IgD- population, 
and it was shown in the present study that Ig-null cells are CD23 negative.  Further, while B1 
cells express CD5 in the peritoneal cavity, they lose surface expression of CD5 when they 
migrate to the periphery. We did not observe CD5 on the Ig-null cells in the peripheral blood of 
this study.   While the developmental process of B1 cells is not as well characterized as B2 cells, 
it is not believed that they participate in germinal center reactions or develop into memory B 
cells as do B2 cells.   
 Based on this information, a model that poses Ig-null cells as B1 cells, is entirely 
plausible (Figure 16).  When a susceptible transplant recipient is initially infected (in the same 
manner as a normal host), B1 cells may become directly infected, or they may become infected 
at some later point when normal latently infected cells (resting memory B2 cells) reactivate and 
infect bystander cells.  Because B1 cells do not obey the rules of the more characterized B2 cells, 
EBV may undergo a burst of replication or clonal proliferation in the peripheral blood to obtain 
high copy numbers of the virus.  Because B1 cells are polyreactive and self-renew in the 
peripheral blood, controls governing the positive selection process for a functional BCR might 
not be as strict as those governing the survival of B2 cells. It is not known whether B1 cells must 
receive the same 2 survival signals as B2 cells.  B cells that have no surface expression of 
immunoglobulin might therefore be able to survive and avoid the apoptotic pathway more easily.  
Most low copy cells in high and low load carriers were IgM+, IgD-.  This implies that most of 
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 the low copy cells did not undergo isotype switching in the germinal center.  As B1 cells are 
known to be IgM+, IgD-, low copy cells could be B1 cells that have not downregulated or 
heavily mutated their immunoglobulin genes.  Experiments to further phenotype Ig-null cells as 
well as to determine the mutations that are preventing the expression of the immunoglobulin 
protein can help confirm or deny this model.   
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Figure 15. The proposed origin of Ig-null cells in the B2 model. 
In this model, newly infected cells originating from the oropharynx enter the germinal center and 
begin to clonally expand and rearrange their V region genes.  Some of these cells also undergo 
amplification of the viral genome, and have nonproductive rearrangements of their heavy chain 
genes.  These cells are rescued by the expression of LMP2a and LMP1 and exit the germinal 
center to persist in the periphery as high copy cells.  These cells may continue to undergo SHM, 
and may begin to lose the hallmarks of B-cell identity.  Alternatively in the germinal center, cells 
may have productive arrangements of their heavy chain locus, and receive survival signals either 
through the accepted means (FDC and T-cell help), or by expression of LMP2a and LMP1.  
These cells exit the germinal center to persist as low copy cells, with the expression of IgM.  In 
rare cases, isotype switching may occur and the low copy cells persist as IgG or IgA+ cells.   
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Figure 16. A model for Ig-null cells as B1 cells.  
In this model, high copy cells originate as B1 cells.  Upon infection, either directly or by 
bystanders, B1 cells either remain as IgM+, low copy cells with little or no activity, or begin to 
rapidly self-renew and amplify the viral genome to become high copy cells.  Many of these cells 
undergo rearrangements of their heavy chain locus, although not during a germinal center 
reaction.   Some of these rearrangements are non-productive.  Survival signals may be provided 
by the LMP molecules, or alternatively, B1 cells may not require the same controls as B2 cells to 
survive in the periphery.   
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 It is clear from the data presented here, along with evidence gathered from the presence 
of Ig-null cells in EBV-associated malignancies, that the relationship between the fate of the B 
cell and infection with EBV is complicated.  The presence of additional factors, including 
immunosuppression complicates the picture further.  It is unclear whether the Ig-null cell 
production preceded the development of a load composed of high copy number EBV genome 
carrying cells, or if B cells were infected before surface immunoglobulin expression was lost.  
Further studies will help clarify such issues.  As Ig-null cells are cells that have lost one of two 
crucial survival signals and should not be present in the peripheral blood, these cells may 
ultimately be proven to be a hallmark for an increased risk of an EBV-driven complication 
following organ transplantation.  Their elimination from the circulation of high load carriers 
would therefore be a great stride in decreasing the incidence of the morbidity and mortality that 
can be associated with transplantation. 
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 5. FUTURE DIRECTIONS 
 
There has been much progress in the characterization of EBV-infected B cells in the peripheral 
blood of pediatric solid organ transplant recipients.  Still, there is much room for growth, 
especially in light of the recent project in which aberrant cells were discovered and documented.  
Most of the future directions in which I see this project going involve being able to sort Ig-null 
cells from PBMC’s with excellent purity.  Fortunately this has been achieved.  One big obstacle 
is cell number.  With the volume of blood that so far has been obtained from Children’s Hospital, 
we have been able to sort no more than 5,000 Ig-null cells from one sample at a time.  For many 
of the proposed future experiments, this issue will need to be addressed. 
 The next logical step in this project is to determine what viral genes are expressed in Ig-
null cells.  It has been shown previously that low load patients have LMP2A transcripts, while 
high load patients demonstrate the presence of both LMP1 and LMP2A transcripts, by reverse-
transcription PCR (RT-PCR) (2).  It will be interesting to note if it is only the Ig-null cells in the 
peripheral blood of high load carriers that are expressing these transcripts or if they are also 
expressed by Ig positive cells.  Ig-null cells are lacking at least one of the major survival signals 
necessary to avoid apoptosis, and in some cases, also lacking the second signal (CD40).  These 
signals can be replaced by the LMP1 and LMP2A viral proteins.  The first step would be to 
determine if these transcripts are present and whether the proteins are made.  This project would 
involve sorting out both Ig-null and Ig-positive cells from PBMC’s of high load patients, 
isolating the RNA, and performing RT-PCR. 
 It would also be advantageous to determine precisely what is preventing the expression of 
immunoglobulin on these cells.  Sequence analysis of the rearrangements of the variable region 
genes in the heavy chain locus would shed light on the origin of the Ig-null cells and show 
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 whether the null cell pool is mono-, oligo-, or polyclonal.  Further, what types of somatic 
mutations are present and if they are crippling would also be determined.  Examples of mutations 
that would lead to Ig-null cells include nonsense mutations, deleterious deletions, and stop 
codons in the coding region.  To achieve this, single Ig-null cells would need to be isolated from 
high load carriers, either by laser capture microscopy or with the FACS Aria.  The IgH 
sequences would be amplified from total genomic DNA with established primer combinations, 
with the PCR product cloned and sequenced.  The changes from the germline in the IgH locus 
would then be analyzed to determine the ratio of the sum of replacement mutations to the sum of 
silent mutations (4).  This ration determines if the cell is a normal antigen selected memory cell 
or if there is a non-antigen selected genotype.  Also, the presence of deletions, stop codons, and 
nonsense mutations would be detected in this manner.   
 One assay that would provide beneficial information about these cells is a cDNA 
microarray, specifically the •Affymetrix GeneChip human genome array.  The level of expression 
of thousands of transcripts could be compared between Ig-null and Ig-positive cells.  In such a 
manner, we would determine if the Ig-null cells have lost any of the B-lineage specific genes, as 
has been observed in the HRS cells of Hodgkin’s Disease (3).  In addition, the survival signals 
that are allowing Ig-null cells to avoid apoptosis might be identified in this manner.  While this 
project would generate vast amounts of data, a large volume of blood from a high load carrier 
would need to be obtained in order to get the minimum cell number.  One recent report suggests 
that a minimum starting number of 50,000 cells is needed to get reliable results with a 
microarray, with one round of RNA amplification (1).  As we currently obtain about 3,000-4,000 
Ig-null cells from each sample, a revision of the protocol is needed.  Some ideas include pooling 
of samples from the one patient with blood obtained at different time points, obtaining a pint of 
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 blood off one high load patient, and generation of an Ig-null cell line.  Each of these has its own 
problems; pooling of samples would need to take into consideration any changes in the health 
status or medication of the patient.  Further, obtaining a pint of blood from one high load patient 
would require special permission and consideration of the patient’s health status.  Finally, 
generation of an Ig-null cell line (see below) might induce changes in the gene expression of the 
Ig-null cells.  
 Outgrowth experiments in which cell lines from Ig-null cells are generated could solve 
the issue of low cell numbers.  We suspect that trial and error would be necessary to encourage 
these cells to proliferate in culture.  If such cell lines were established, a number of potential 
experiments could be proposed.  In situ hybridization and immunofluorescense to confirm both 
the phenotype and high copy status of Ig-null cells would be one easily conducted experiment.   
 It is clear that with the discovery of Ig-null cells in the peripheral blood of pediatric solid 
organ transplant recipients, many more questions are generated.  While they are beyond the 
scope of the current project, the potential for growth in this area is boundless.  More information 
about Ig-null cells in transplant recipients could lead to advances in the prevention and treatment 
of EBV-associated PTLDs. 
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 APPENDIX A:  List of Abbreviations 
 
AIDS  Acquired immunodeficiency syndrome 
AILD  Angioimmunoblastic Lymphadenopathy with Dysproteinemia 
ASM  American Society of Microbiology 
BCR  B-cell receptor 
BL  Burkitt’s Lymphoma 
C3d  complement protein C3 degradation fragment d 
CD  cluster of differentiation 
CHP  Children’s Hospital of Pittsburgh 
CMV  Cytomegalovirus 
CNS  central nervous system 
CTL  cytotoxic T lymphocyte 
DIG  digoxigenin 
DNA  deoxyribonucleic acid 
DS  dyad symmetry element 
dUTP  deoxyuridine triphosphate 
EA  early antigen 
EBER  Epstein-Barr virus encoded RNA 
EBNA  Epstein-Barr virus nuclear antigen 
EBNA-LP Epstein-Barr virus nuclear antigen - leader protein 
EBV  Epstein-Barr Virus 
EDTA  ethylenediaminetetra-acetic-acid 
FACS  fluorescence activated cell sorting 
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 FISH  fluorescent in situ hybridization 
FITC  fluorescein isothiocyanate 
FR  family of repeats 
gp  glycoprotein 
GVHD  Graft versus Host Disease 
HCC  high copy cells 
HD  Hodgkin’s Disease 
HHV4  human herpesvirus 4 
HIV  Human immunodeficiency virus 
HLA  human leukocyte antigen 
HLC  high load carrier 
HRS  Hodgkin and Reed Sternberg cells 
HSCT  hematopoietic stem cell transplant 
IF  immunofluorescence 
Ig  immunoglobulin 
IL  interleukin 
IM  infectious mononucleosis 
IR  internal repeat 
kb  kilobase 
kd  kilodalton 
LCC  low copy cells 
LCL  lymphoblastoid cell line 
LCV  lymphocryptovirus 
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 LLC  low load carrier 
LMP  latent membrane protein 
MAC  magnetic activated cell sorting 
MoFLo modular flow high performance cell sorter 
ND  non-detectable 
NK  natural killer cell 
NPC  Nasopharyngeal carcinoma 
PBMCs peripheral blood mononuclear cells 
PBS  phosphate buffered saline 
PCR  polymerase chain reaction 
PE  phycoerythrin 
PEL  primary effusion lymphoma 
PTLD  post-transplant lymphoproliferative disease 
QC-PCR quantitative-competitive polymerase chain reaction 
RDV  rhadinovirus 
RNA  ribonucleic acid  
RT-PCR reverse-transcriptase polymerase chain reaction 
SAGE  serial analysis of gene expression 
sIg  surface immunoglobulin 
SOT  solid organ transplantation 
TR  terminal repeat 
VCA  viral capsid antigen 
XLP  X-linked lymphoproliferative disease 
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